Following a three month consultation period, this is the final version of the Upper GI measures for inclusion within the Manual for Cancer Services. The measures can also be found on the CQUINS website at www.cquins.nhs.uk

Contact Details
Zara Gross
Project Assistant National Cancer Peer Review,
National Cancer Action Team
18th Floor, Portland House
Bressenden Place
London, SW1E 5RS
## Contents

### 11-1C-1f - FUNCTIONS OF NETWORK SITE SPECIFIC GROUPS (NSSGs)

<table>
<thead>
<tr>
<th>Measure Number</th>
<th>Measure</th>
</tr>
</thead>
<tbody>
<tr>
<td>11-1C-101f</td>
<td>NSSG Meeting</td>
</tr>
<tr>
<td>11-1C-102f</td>
<td>Annual Review, Work Programme and Annual Report</td>
</tr>
<tr>
<td>11-1C-103f</td>
<td>Network Agreed Clinical Guidelines</td>
</tr>
<tr>
<td>11-1C-104f</td>
<td>Network Agreed Imaging Guidelines</td>
</tr>
<tr>
<td>11-1C-105f</td>
<td>Network Agreed Pathology Guidelines</td>
</tr>
<tr>
<td>11-1C-106f</td>
<td>Agreed Minimum Dataset</td>
</tr>
<tr>
<td>11-1C-107f</td>
<td>Network Audit</td>
</tr>
<tr>
<td>11-1C-108f</td>
<td>Discussion of Clinical Trials</td>
</tr>
<tr>
<td>11-1C-109f</td>
<td>Agreed NSSG Three Year Service Delivery Plan</td>
</tr>
<tr>
<td>11-1C-110f</td>
<td>Chemotherapy Treatment Algorithms</td>
</tr>
<tr>
<td>11-1C-111f</td>
<td>The TYACN Pathway for Initial Management</td>
</tr>
<tr>
<td>11-1C-112f</td>
<td>The TYA Pathway for Follow Up on Completion of First Line Treatment</td>
</tr>
<tr>
<td>11-1C-113f</td>
<td>Agreed Named Members and Agreed Terms of Reference for NSSG</td>
</tr>
<tr>
<td>11-1C-114f</td>
<td>Primary Care Referral Policy</td>
</tr>
<tr>
<td>11-1C-115f</td>
<td>Network Configuration of Teams</td>
</tr>
<tr>
<td>11-1C-116f</td>
<td>Network Agreed Referral Guidelines Between Teams</td>
</tr>
</tbody>
</table>

### 11-2F-1 - DIAGNOSTIC AND DIAGNOSTIC/LOCAL CARE UPPER GI MULTIDISCIPLINARY TEAM (MDT)

<table>
<thead>
<tr>
<th>Measure Number</th>
<th>Measure</th>
</tr>
</thead>
<tbody>
<tr>
<td>11-2F-101</td>
<td>Lead Clinician and Core Team Membership</td>
</tr>
<tr>
<td>11-2F-102</td>
<td>Level 2 Practitioners for Psychological Support</td>
</tr>
<tr>
<td>11-2F-103</td>
<td>Support for Level 2 Practitioners</td>
</tr>
<tr>
<td>11-2F-104</td>
<td>Team Attendance at NSSG Meetings</td>
</tr>
<tr>
<td>11-2F-105</td>
<td>MDT Meetings</td>
</tr>
<tr>
<td>11-2F-106</td>
<td>MDT Agreed Cover Arrangements for Core Member</td>
</tr>
<tr>
<td>11-2F-107</td>
<td>Core Member (or cover) Present for 2/3 of Meetings</td>
</tr>
<tr>
<td>11-2F-108</td>
<td>Annual Meeting to Discuss Operational Policy</td>
</tr>
<tr>
<td>11-2F-109</td>
<td>Policy for All New Patients to be Reviewed by MDT</td>
</tr>
<tr>
<td>11-2F-110</td>
<td>MDT Agreement to Network Guidelines for the Management Upper GI Cancer</td>
</tr>
<tr>
<td>Measure Number</td>
<td>Measure</td>
</tr>
<tr>
<td>----------------</td>
<td>---------</td>
</tr>
<tr>
<td>11-2F-111</td>
<td>Policy for Communication of Diagnosis to GP</td>
</tr>
<tr>
<td>11-2F-112</td>
<td>MDT Agreement to Network Follow Up Guidelines</td>
</tr>
<tr>
<td>11-2F-113</td>
<td>Operational Policy for Named Key Worker</td>
</tr>
<tr>
<td>11-2F-114</td>
<td>Core Histopathology Member(s) Participating in EQA Scheme</td>
</tr>
<tr>
<td>11-2F-115</td>
<td>Core Nurse Member Completed Specialist Study</td>
</tr>
<tr>
<td>11-2F-116</td>
<td>Core Nurse Responsibilities</td>
</tr>
<tr>
<td>11-2F-117</td>
<td>Attendance at National Advanced Communication Skills Training Programme</td>
</tr>
<tr>
<td>11-2F-118</td>
<td>Extended Membership of MDT</td>
</tr>
<tr>
<td>11-2F-119</td>
<td>Extended Membership to include specialist palliative care representative and dietician</td>
</tr>
<tr>
<td>11-2F-120</td>
<td>Patient Permanent Consultation Record</td>
</tr>
<tr>
<td>11-2F-121</td>
<td>Patient Experience Exercise</td>
</tr>
<tr>
<td>11-2F-122</td>
<td>Provision of Written Patient Information</td>
</tr>
<tr>
<td>11-2F-123</td>
<td>Agree and Record Individual Patient Diagnosis and Referral</td>
</tr>
<tr>
<td>11-2F-124</td>
<td>MDT Agreement to Network Clinical Guidelines for the Management of Upper GI Cancer</td>
</tr>
<tr>
<td>11-2F-125</td>
<td>MDT Agreement to Network Referral Guidelines (diagnostic)</td>
</tr>
<tr>
<td>11-2F-126</td>
<td>MDT Agreement to Network Referral Guidelines (diagnostic/local care)</td>
</tr>
<tr>
<td>11-2F-127</td>
<td>MDT Agreement to Network Imaging Guidelines</td>
</tr>
<tr>
<td>11-2F-128</td>
<td>MDT Agreement to Network Pathology Guidelines</td>
</tr>
<tr>
<td>11-2F-129</td>
<td>Agreed Collection of Minimum Dataset</td>
</tr>
<tr>
<td>11-2F-130</td>
<td>Network Audit</td>
</tr>
<tr>
<td>11-2F-131</td>
<td>Discussion of Clinical Trials</td>
</tr>
<tr>
<td>11-2F-132</td>
<td>Joint Treatment Planning for TYAs</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Measure Number</th>
<th>Measure</th>
</tr>
</thead>
<tbody>
<tr>
<td>11-2F-201</td>
<td>Lead Clinician and Core Team Membership</td>
</tr>
<tr>
<td>11-2F-202</td>
<td>Level 2 Practitioners for Psychological Support</td>
</tr>
<tr>
<td>11-2F-203</td>
<td>Support for Level 2 Practitioners</td>
</tr>
<tr>
<td>11-2F-204</td>
<td>Team Attendance at NSSG Meetings</td>
</tr>
<tr>
<td>11-2F-205</td>
<td>MDT Meetings</td>
</tr>
<tr>
<td>11-2F-206</td>
<td>MDT Agreed Cover Arrangements for Core Member</td>
</tr>
<tr>
<td>11-2F-207</td>
<td>Core Member (or Cover) Present for 2/3 of Meetings</td>
</tr>
<tr>
<td>11-2F-208</td>
<td>Annual Meeting to Discuss Operational Policy</td>
</tr>
<tr>
<td>11-2F-209</td>
<td>Policy for All New Patients to be Reviewed by MDT</td>
</tr>
<tr>
<td>Measure Number</td>
<td>Measure</td>
</tr>
<tr>
<td>----------------</td>
<td>---------</td>
</tr>
<tr>
<td>11-2F-210</td>
<td>Policy for Communication of Diagnosis to GP</td>
</tr>
<tr>
<td>11-2F-211</td>
<td>MDT Agreement to Network Specialist Team Policy for Referral Discussion</td>
</tr>
<tr>
<td>11-2F-212</td>
<td>MDT Meeting with Referring Teams/Collaborative Audit</td>
</tr>
<tr>
<td>11-2F-213</td>
<td>MDT Agreement to Network Follow Up Guidelines</td>
</tr>
<tr>
<td>11-2F-214</td>
<td>24-Hour On-Call Consultant Specialist Surgical Cover</td>
</tr>
<tr>
<td>11-2F-215</td>
<td>Intensive Care (ITU) and High Dependency Unit (HDU) in Host Hospital</td>
</tr>
<tr>
<td>11-2F-216</td>
<td>Single Site Surgery and Post Operative Care</td>
</tr>
<tr>
<td>11-2F-217</td>
<td>Operational Policy for Named Key Worker</td>
</tr>
<tr>
<td>11-2F-218</td>
<td>Histopathology Core Members Participating in EQA Scheme</td>
</tr>
<tr>
<td>11-2F-219</td>
<td>Core Nurse Member Completed Specialist Study</td>
</tr>
<tr>
<td>11-2F-220</td>
<td>Core Nurse Responsibilities</td>
</tr>
<tr>
<td>11-2F-221</td>
<td>Attendance at National Advanced Communication Skills Training Programme</td>
</tr>
<tr>
<td>11-2F-222</td>
<td>Extended Membership of MDT</td>
</tr>
<tr>
<td>11-2F-223</td>
<td>Patient Permanent Consultation Record</td>
</tr>
<tr>
<td>11-2F-224</td>
<td>Patient Experience Exercise</td>
</tr>
<tr>
<td>11-2F-225</td>
<td>Provision of Written Patient Information</td>
</tr>
<tr>
<td>11-2F-226</td>
<td>Individual Patient Treatment Plans</td>
</tr>
<tr>
<td>11-2F-227</td>
<td>MDT Agreement to Network Guidelines for the Management of Upper GI Cancer</td>
</tr>
<tr>
<td>11-2F-228</td>
<td>MDT Agreement to Network Referral Guidelines Between Teams/Diagnosis &amp; Assessment</td>
</tr>
<tr>
<td>11-2F-229</td>
<td>MDT Agreement to Network Imaging Guidelines Diagnosis/Assessment</td>
</tr>
<tr>
<td>11-2F-230</td>
<td>MDT Agreement to Network Pathology Guidelines Diagnosis/Assessment</td>
</tr>
<tr>
<td>11-2F-231</td>
<td>Agreed Collection of Minimum Dataset</td>
</tr>
<tr>
<td>11-2F-232</td>
<td>Network Audit</td>
</tr>
<tr>
<td>11-2F-233</td>
<td>Discussion of Clinical Trials</td>
</tr>
<tr>
<td>11-2F-234</td>
<td>Joint Treatment Planning for TYAs</td>
</tr>
</tbody>
</table>
INTRODUCTION

1 Introduction

The National Cancer Peer Review Programme provides important information about the quality of clinical teams and a national benchmark of cancer services across the country. It aims to improve care for people with cancer and their families by:

- ensuring services are as safe as possible;
- improving the quality and effectiveness of care;
- improving the patient and carer experience;
- undertaking independent, fair reviews of services;
- providing development and learning for all involved;
- encouraging the dissemination of good practice.

The benefits of peer review have been found to include the following:

- provision of disease specific information across the country together with information about individual teams which has been externally validated;
- provision of a catalyst for change and service improvement;
- identification and resolution of immediate risks to patients and/or staff;
- engagement of a substantial number of front line clinicians in reviews;
- rapid sharing of learning between clinicians, as well as a better understanding of the key recommendations in the NICE guidance.

The Manual for Cancer Services is an integral part of Improving Outcomes: A Strategy for Cancer and aligns with the aims of the Coalition Government: to deliver health outcomes that are among the best in the world. The Manual supports the National Cancer Peer Review quality assurance programme for cancer services and enables quality improvement both in terms of clinical and patient outcomes. The Manual includes national quality measures for site specific cancer services together with cross cutting services such as chemotherapy and radiotherapy.

The Report of Mid Staffordshire NHS Foundation Trust Public Inquiry (Robert Francis Jan 2013) said the creation of a caring culture would be greatly assisted if all those involved in the provision of healthcare are prepared to learn lessons from others and to offer up their own practices for peer review. Whilst peer review will have a specific relevance in cases of practitioners where there may be concerns about substandard performance, it has a far more fundamental role in changing behaviour to ensure a consistent and caring culture throughout the healthcare services. Peer review therefore needs to be a key part of the delivery and monitoring of any service or activity, and those involved need to demonstrate that this element of monitoring and learning is integral to the process of compliance with fundamental standards and of improvement. Among the recommendations made is recommendation 49, Enhancement of monitoring and the importance of inspection, which states:

Routine and risk-related monitoring, as opposed to acceptance of self-declarations of compliance, is essential. The Care Quality Commission should consider its monitoring in relation to the value to be obtained from:

- The Quality and Risk Profile;
- Quality Accounts;
- Reports from Local Healthwatch;
- New or existing peer review schemes;
- Themed inspections.

1.1 National Cancer Measures

The development of cancer measures is a dynamic process in order to:

- reflect new NICE Quality Standards and clinical guidelines and revisions to existing NICE guidance;
• allow greater influence by users of cancer services and their carers;
• allow greater influence by clinicians;
• take account of possible modifications to measures following peer review visits;
• ensure the scope of measures encompasses the broader implementation of the Improving Outcomes: A Strategy for Cancer;
• reflect new developments and initiatives in treatment and patient care;
• reflect the NHS Commissioning Board specialised service specifications.

1.2 Clinical Indicators/Outcomes

Peer review is changing its emphasis to focus on both clinical and patient outcomes. In order to achieve this, clinical indicators have been introduced and form part of the review process along with a reduced number of structure and process measures.

2 Interpretation of the National Manual for Cancer Services

2.1 Guidance Compared to Cancer Measures

National guidance is exactly what it says - guidance in general and indeed is excellent for this purpose. Guidance involves giving advice and recommendations on how things should be done now, in the future and sometimes on how things should have been done for sometime already. It may involve describing in effect the "perfect" service, using phrases like "the best possible", "to all patients at all times", etc. It may involve all-inclusive, far-ranging objectives and aspirations involving many agencies in long, interlinked chains of events and tasks which all have to be fulfilled before the desired outcome of the guidance is achieved. A particular person's accountability for each task is often not stated. Without this underlying type of mind-set guidance would not inspire, lead, motivate or guide and would probably be almost unreadable.

The Manual for Cancer Services has to take a different approach. It is written for the specific purpose of being used to assess a service; to aid self assessment and team development; to be fair compared to visits to other services elsewhere and to past and future visits to the same service. Therefore, the measures have to:

• be objective;
• be measurable;
• be specific, clear and unambiguous;
• be verifiable;
• state who exactly is responsible for what;
• be discriminating;
• be achievable;
• be developmental - encourage continuous quality improvement and not produce destructive competition or a sense of failure.

2.2 "The Responsibility for Assessment Purposes"

This refers to the fact that someone, or some group, is always held nominally responsible for compliance with each one of the quality measures. This has to be specified or, in terms of organising the peer review and collecting the results, it would be unclear who was being held as compliant or non-compliant or who the results could be attributed to. Where it is unclear who has responsibility there tends to be inertia. This attribution of responsibility does not necessarily commit a given person to actually carrying out a given task - this can be delegated according to local discretion, unless it is clear that a given task really is limited to a certain group.

2.3 "Agreement"

Where agreement to guidelines, policies etc. is required, this should be stated clearly on the cover sheet of the three key documents including date and version. Similarly, evidence of guidelines, policies etc. requires written evidence unless otherwise specified. The agreement by a person representing a group or team (chair
or lead etc.) implies that their agreement is not personal but that they are representing the consensus opinion of that group.

2.4 Confirmation of Compliance

Compliance against certain measures will be the subject of spot checks or further enquires by peer reviewers when a peer review visit is undertaken. When self assessing against these measures a statement of confirmation of compliance contained within the relevant key evidence document will be sufficient.

2.5 "Quality" Aspects of Cancer Service Delivery

The peer review process recognises the qualitative as well as quantitative aspects of review and in addition to the objective recording of compliance against the measures there is a narrative part to the report that provides an overall summary of a team’s performance.

Manual for Cancer Services On-line

An on-line version of the Manual for Cancer Services has been developed. The on-line version allows individuals to identify and extract measures by tumour site, organisation type and subject area in a variety of formats.

The on-line manual can be accessed from the CQuINS web site at http://www.cquins.nhs.uk
Introduction

The Improving Outcomes Guidance (IOG) Upper GI tract cancer has further developed the concepts previously used for gynae cancer. The latter involved a simple division between centre and unit teams with instructions on distribution of work. Thus, for Upper GI (UGI) tract cancer the guidance describes a network-wide structure of team types with more detailed instructions on how these teams should relate to each other and to primary care. The specific configuration of teams in a given centre or unit may take different forms depending on the catchment population and the overall structure of the service in the network to which the centre or unit belongs. The recommended minimum catchment population is 1 million for oesophago-gastric (OG) cancer and 2 million for pancreatic cancer. These considerations have determined the format of this section of the measures and have necessitated specific measures for UGI tract cancer for the network site specific group. These have been incorporated into UGI-specific parts of the network measures, which have been attached to the UGI measures. The measures also move more into the areas of the diagnostic process and liaison with primary care. This has been considered necessary because the organisation of the diagnostic process has such an obvious and far-reaching effect on the overall pathway of those patients who are subsequently found to have the disease.

It is recognised that the changes necessary to achieve full compliance with these measures will take time and resources. A given network may need to take a phased approach to this (over transfer of workload for instance).

Levels of Care

There are three defined levels of care:

a) The diagnostic process
b) Local care

c) Specialist Care

All patients diagnosed with UGI cancer should be individually discussed with a member of the specialist team (see references to 'teams' below), prior to any proposed treatment. Subject to this and subject to agreement in the network's own guidelines, local care may be delivered under the care of a member(s) of the local UGI team.

The treatment and procedures classed in these measures as local care are:

i) Palliative surgical bi-pass procedures
ii) Palliative stenting
iii) Other endoscopic debulking methods to clear blockage by tumour, except intraluminal radiotherapy
iv) Palliative chemotherapy
v) Palliative and supportive care, not involving active, tumour shrinking or debulking therapy.

Procedures classed as local care may also be delivered under the care of a member(s) of the specialist team.

c) Specialist Care

This should only be delivered under the care of a member(s) of the specialist team (see references to 'teams' below) and this is not subject to change by the network's own guidelines.
The treatments and procedures classed in these measures as specialist care are:

i) All tumour resective surgery, whether with curative or palliative intent. In addition to being under the care of specialist team members, this should only be carried out in the host hospital of the specialist team.

ii) The following treatments, which should be delivered under the care of a member of the specialist team but the site of delivery is subject to agreement in the network's guidelines:
   iii) Chemo/radiotherapy
   iv) Adjuvant chemotherapy (recommended currently only for gastric cancer)
   v) Intraluminal radiotherapy.

Notes:

- Emergency surgical procedures where the diagnosis is unforeseen and is made at the time of the operation, are not subject to these measures.
- Palliative external beam radiotherapy has only a limited role in the treatment of primary UGI cancer and would be delivered in the radiotherapy department. It is not mandatorily covered by these measures.

Shape of the Service

a) The diagnostic process should be carried out by a defined diagnostic team which liaises with primary care over the "guidelines for urgent referral for suspected cancer". The team refers cancer patients to other teams providing local care or specialist care.

It can be foreseen that some small hospitals far from other services would host a diagnostic team in isolation. However, by applying an underlying principle of the IOG Upper GI tract guidance, i.e. consolidation of services for a group of relatively rare cancers, then in most instances the diagnostic team will also offer local care to the relevant local patients.

Following the same principle and the fact that both the diagnostic process and local care will largely be undertaken by the same personnel, it is recommended local care teams should not exist in isolation from the diagnostic process. Therefore the measures refer to diagnostic and combined diagnostic/local care teams, the latter comprising of the diagnostic team with some modifications. For the special situation where a population is served by a local hospital hosting a specialist team, there are different arrangements for the diagnostic process and local care delivery which are described later.

b) Specialist care should be provided by defined and separate specialist teams for OG cancer and pancreatic cancer. With reference to the team's catchment population, the 1 million minimum for OG means that some localities and even some smaller networks will not be able to have a team. The 2 million population minimum for pancreatic cancer means that currently, in England, no network on the basis of its own catchment population will be able to have more than one pancreatic team.

A further principle in the IOG Upper GI guidance is that the meetings, surgical operations and acute post-operative care (including HDU and ITU) of a given specialist team should all take place in one hospital. This principle, together with the minimum catchment populations and the principle of consolidation of services for a group of relatively rare cancers have the following important implications:

- In a given trust which has a specialist OG team, it should be the only OG team for that trust.
- In a given trust which has a specialist pancreatic team it should be the only pancreatic team for that trust.

The exact boundaries of what constitutes a team and what does not, as outlined in the introduction to MDTs, is especially important here.
c) The diagnostic process and the delivery of local care for the local population of a hospital hosting a specialist team will now be considered. It is important to ensure that the specialist team experiences the management of the whole spectrum of severity of its cancer type. This and again the principle of consolidation of services for a group of relatively rare cancers means that specialist teams should also provide the local care for the secondary referral (local) catchment population of the locality to which they belong unless this imposes excessive travel requirements on frail patients. Furthermore this means that in a locality with only a specialist OG team this team should provide local care for pancreatic as well as OG cancer. A locality with a pancreatic team will also be large enough for an OG team so each will provide local care for its own cancer type. In a locality with a specialist team working in accordance with the guidance entirely in a single hospital, there may therefore be other hospitals classed as part of that locality which provide diagnostic teams which refer directly to the specialist team for both specialist and local care.

The principles outlined above mean that a unified agreement over the service configuration is needed across the whole of each network and possibly (particularly in the case of pancreatic specialist teams) between neighbouring networks involving inter-network referrals.

Configurations

These implications of the guidance lead to the following possible service configurations within a given locality which may be offered for assessment having first been agreed by the relevant NHSCB Area Team. Their agreement is the overall responsibility of the Medical Director of the Area Team.

- **Locality (>2m) with specialist teams for pancreatic and OG cancer, and diagnostic team(s).**
  a) Single specialist/local care team for pancreatic cancer; and
  b) Single specialist/local care team for OG cancer; and
  c) One or more diagnostic teams conforming to the referral agreement between the NSSG and primary care for the secondary referral catchment population of the locality.

  **Note:**  
  It is recommended that local care for the locality's secondary catchment population is provided by the specialist teams. In exceptional circumstances where this produces excessive travelling for frail patients, the extension of named diagnostic teams to provide local care in named locations should be agreed by the NSSG.

- **Locality (>1m; <2m) with specialist team for OG and diagnostic team(s).**
  a) Single specialist team giving OG specialist care and local care for both OG and pancreatic.
  b) One or more diagnostic teams conforming to the referral agreement between the NSSG and primary care for the secondary referral catchment population of the locality.

  **Note:**  
  It is recommended that local care for the locality's secondary catchment population is provided by the specialist team. In exceptional circumstances where this produces excessive travelling for frail patients, the extension of named diagnostic teams to provide local care in named locations should be agreed by the NSSG.

- **Locality (<1m) with no specialist teams.**
  a) A single diagnostic/local care team.

  **Note:**  
  In exceptional circumstances where this produces excessive travelling for frail patients, the establishment of more than one named diagnostic/local care team in named locations should be agreed by the Network Board (see topic 1A).
Building the UGI Cancer Network

The logical progression for building the UGI Cancer Network is as follows:

i) Agree the identity and location of diagnostic UGI teams for the network.
ii) Agree the referral arrangements between primary care and diagnostic teams.
iii) Find the referring catchment population of each diagnostic team from the numbers associated with its referring practices.
iv) Agree the configuration of diagnostic/local care/specialist teams for the network.
v) Agree the specific referral guidelines between teams across the network and if necessary between neighbouring networks.
vi) Confirm the referring catchment populations of each specialist team by adding the populations of the teams own referring diagnostic teams.
How the configurations work

The following figure illustrates examples of the configurations and how a typical group of localities would relate, according to the measures, within and across networks.

**NETWORK 1**
Pop: >2M
(own catchment, or plus neighbouring network for pancreatic referrals).

**LOCALITY <1M**
Diagnostic/local care team

**LOCALITY (>2m referral catchment)**
- Specialist/local care pancreas team
- Specialist/local care OG team
  - Pancreatic cancer
  - OG Cancer
  - Diagnostic

**LOCALITY (>1m <2m referral catchment)**
- Specialist OG/local care OG & pancreas team
  - Local care pancreatic
  - All OG Ca
  - Diagnostic

**NETWORK 2**
Pop: >1m <2m

**LOCALITY (>1m <2m referral catchment)**
- Specialist OG/local care OG & pancreas team
  - Local care pancreatic
  - All OG Ca
  - Diagnostic

= A Team
= A Locality

UPPER GI SPECIFIC MEASURES  GATEWAY No. 10790 - APRIL 2013  13
TOPIC 11-1C-1f - FUNCTIONS OF NETWORK SITE SPECIFIC GROUPS (NSSGs)

Introduction

The measures in this section should be applied separately to each NSSG. Thus there will be as many sets of compliance results as there are NSSGs.

Prior to review, the boundaries of the network to be reviewed should be agreed with the relevant Strategic Clinical Networks (SCNs) and a named SCN should agree to take responsibility for the purpose of the peer review, for managing the immediate process of dealing with the outcomes of the review.

NB For this transition year the measures for NSSGs that were previously applied to the network board (1A) have been incorporated into these measures (1C). These have all been added to the end, so as not to disrupt the established measure numbers.

<table>
<thead>
<tr>
<th>MEASURE DETAILS &amp; DEMONSTRATION OF COMPLIANCE</th>
</tr>
</thead>
<tbody>
<tr>
<td>GENERAL ACTIVITIES</td>
</tr>
<tr>
<td>NSSG Meeting</td>
</tr>
<tr>
<td><strong>11-1C-101f</strong></td>
</tr>
<tr>
<td>The NSSG should meet regularly and record attendance.</td>
</tr>
<tr>
<td>Note:</td>
</tr>
<tr>
<td>The attendance of MDT representatives is reviewed as part of each MDT’s measures.</td>
</tr>
<tr>
<td>Compliance:</td>
</tr>
<tr>
<td>A list of meetings and attendance records in the last 12 months.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Annual Review, Work Programme and Annual Report</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>11-1C-102f</strong></td>
</tr>
<tr>
<td>The NSSG should have agreed an annual work programme.</td>
</tr>
<tr>
<td>The NSSG should have produced an annual report.</td>
</tr>
<tr>
<td>Compliance:</td>
</tr>
<tr>
<td>The annual work programme agreed by the Chair of the NSSG.</td>
</tr>
<tr>
<td>The annual report agreed by the Chair of the NSSG.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>CLINICAL GUIDELINES</th>
</tr>
</thead>
<tbody>
<tr>
<td>Network Agreed Clinical Guidelines</td>
</tr>
<tr>
<td><strong>11-1C-103f</strong></td>
</tr>
<tr>
<td>The NSSG should agree network-wide clinical guidelines (how a given patient should be clinically managed, usually at the level of which modality of treatment is indicated, rather than detailed regimens or surgical techniques).</td>
</tr>
<tr>
<td>Notes:</td>
</tr>
<tr>
<td>• More details of regimens and techniques may be agreed if desired.</td>
</tr>
<tr>
<td>• See further instructions on clinical guidelines for UGI cancer.</td>
</tr>
<tr>
<td>Compliance:</td>
</tr>
<tr>
<td>The clinical guidelines agreed by the Chair of the NSSG.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>IMAGING GUIDELINES</th>
</tr>
</thead>
<tbody>
<tr>
<td>Network Agreed Imaging Guidelines</td>
</tr>
<tr>
<td><strong>11-1C-104f</strong></td>
</tr>
<tr>
<td>The NSSG should agree network-wide imaging guidelines for diagnosis and review. The guidelines should address:</td>
</tr>
</tbody>
</table>
MEASURE DETAILS & DEMONSTRATION OF COMPLIANCE

- imaging modalities;
- their specific indications.

Compliance: The imaging guidelines agreed by the Chair of the NSSG.

PATHOLOGY GUIDELINES

For compliance with this measure the NSSG should, in consultation with the MDTs and the network cancer pathology group, produce the network-wide cancer pathology guidelines. Each individual MDT, for their compliance with the relevant measure on pathology guidelines in the MDT should agree to them.

Network Agreed Pathology Guidelines

11-1C-105f The NSSG should agree network-wide pathology guidelines for diagnosis and assessment. The guidelines should address:

- laboratory and histopathological/histochemical investigations;
- their specific indications.

Compliance: The pathology guidelines agreed by the Chair of the NSSG.

Agreed Minimum Dataset

11-1C-106f The NSSG should agree an area-wide minimum dataset (MDS) which covers at least the latest approved cancer dataset at www.isb.nhs.uk.

The NSSG may wish to agree additional data items such as:

- the cancer waiting times monitoring, including Going Further on Cancer Waits in accordance with DSCN 20/2008, to the specified timetable as specified in the National Contract for Acute Service;

The MDS must include all items required for the national contract; any additional items should use definitions and codes taken from the National Cancer Dataset and the NHS Data Dictionary.

The NSSG should agree a network-wide policy specifying:

- which team should collect which portion of the MDS;
- when each data items should be captured on the patient pathway;
- how the data will be stored and managed within local data systems.

Compliance: The MDS agreed by the Chair of the NSSG.

The policy agreed by the Chair of the NSSG.

Note: The NSSG for their compliance with this measure should, in consultation with the MDTs, agree the MDS and the individual MDTs, for compliance with their relevant measure, should agree to collect it.

NETWORK AUDIT

Introductory Notes

For review purposes a network audit project is an audit project related to the cancer site or sites of the NSSG and the activities of its MDTs. The same project should be carried out by all MDTs for that cancer site in the network, each team's results being separately identified. The individual MDTs, for compliance with their relevant MDT measure, should agree to participate in the audit. See appendix 1 for audit.

Network Audit

11-1C-107f The NSSG should agree a network audit project.

The NSSG should annually review the progress of the audit project or discuss the results of the completed area audit project.

Note: Where national audits have been developed these should be part of the area audit
programme.

Additional projects may be agreed.

Compliance: The project agreed by the Chair of the NSSG.

Written confirmation of an annual review sufficient to how compliance with the measures.

Note: An agreed summary is sufficient provided it shows compliance with the measure.

Discussion of Clinical Trials

11-1C-108f

The NSSG should discuss at least annually, the report on clinical trials from each of its MDTs (see relevant MDT measures).

The following should be present at the discussion:

- the Chair of the NSSG or a nominated representative;
- the NSSG research lead;
- the lead clinician of the MDT or nominated representative from that MDT;
- the clinical lead of the research network or a nominated representative from the research network.

A programme for improvement for clinical trial entry for the MDT should be agreed at the discussion.

Compliance: Confirmation of discussions, sufficient to show compliance with the measure, including those present.

The programmes for improvement, agreed by the lead clinicians of the MDTs and the clinical lead of the cancer research network.

Notes: The discussion with various individual MDTs may take place at different meetings of the NSSG. All of the MDTs of the NSSG need to have attended such a meeting for the measure to be compliant.

Agreed NSSG Three Year Service Delivery Plan

11-1C-109f

The NSSG should agree proposed service developments for its cancer site for three contracting years, as advice to the board for the network proposed service delivery plan.

Compliance: The plan agreed by the Chair of the NSSG.

CHEMOTHERAPY TREATMENT ALGORITHMS

Introduction

- For the purposes of peer review, a chemotherapy regimen is defined by the therapeutic chemotherapy drugs used, often expressed as an acronym e.g. ‘FEC’. A change of one or more of these drugs themselves would normally be necessary for it to be classed as a change of regimen. In some cases major changes in the dose or route of administration of one or more of the drugs effectively changes the regimen but these cases are generally known and recognised nationally. A given network is free to choose any further changes which they classify as changing the regimen, as long as it is in accord with the above definition and national exceptions; i.e. they are free to make the definition of a regimen narrower, but not wider.

- For the purposes of peer review, a chemotherapy treatment protocol is defined as constituting all the parameters specified in the bullet points in chemotherapy measure 11-3S-122. A change in any of these parameters would change the treatment protocol but any change other than the therapeutic drugs themselves (apart from the national and local exceptions specified above) would change only the protocol, not the regimen as well.

- For the purposes of peer review a chemotherapy treatment algorithm may be described as a guideline which specifies the acceptable ranges of regimen options for named steps on the patient pathway. Treatment algorithms are cancer site-specific. They are not specific to individual patients, i.e. they are not individual treatment plans. Thus, a treatment algorithm for breast cancer would include a statement of the range of regimens agreed as acceptable for adjuvant chemotherapy and for first, second and third line palliative chemotherapy etc. Illustrative examples of treatment algorithms in different formats may be found in appendix 1 in the chemotherapy measures. There may be other formats which would be acceptable to the reviewers. Thus, a change of regimen or order of regimens may no longer comply with a previous treatment algorithm, but a change of one of the minor aspects of a treatment protocol.
Chemotherapy Treatment Algorithms

The NSSG, in consultation with the Network Chemotherapy Group (NCG) should agree a list of acceptable chemotherapy treatment algorithms. It should be updated bi-annually.

Notes:

- The intention is not to require a single mandatory regimen for each clinical indication. It is to prevent individual practitioners having unorthodox, obsolete and unpredictably varying practice, which is against the opinion of their peers within the network.
- The NSSG should produce the algorithms for its compliance with this measure and the chemotherapy multi-professional team should produce a compatible list of algorithms for the NSSG’s cancer site for their own service (measure 11-3S-122).
- The chemotherapy multi-professional team should agree lists with all the NSSGs relevant to their practice, for compliance with their measure.
- The network algorithm for a particular clinical situation may have a number of alternative regimens of which the multi-professional team need only agree those which it intends to use in its service. The multi-professional team need only address those clinical indications which are applicable to the scope of its practice. The key requirement is that all the algorithms on the multi-professional team list are compatible with the NSSG agreed list.
- This exercise should include oral chemotherapy.
- This measure is assessed as part of the responsibility of each NSSG, but from the NCG’s point of view regarding the management of this process, the algorithms don’t all need to be updated at the same time. It would seem sensible, however, to update all those for a given cancer site, at the same time.

Compliance: The algorithms in place prior to the self assessment/peer review visit agreed by the Chair of the NSSG, and the Chair of the NCG.

For NSSGs meeting for three or more years since the publication of the measures, the algorithms are needed from the first year, then the agreed updates every two years up to the self assessment/peer review visit.

The TYACN Pathway for Initial Management

The NSSG should agree, with the chair of the relevant TYACNCG, the TYACN patient pathway for initial management, including any features specific to the NSSG’s cancer site and their host adult cancer network and incorporating their relevant MDT contact numbers.

The NSSG should distribute the pathway to the lead clinicians of the MDTs of their cancer site in their host cancer network.

Compliance: The pathway, agreed by the Chair of the NSSG and the chair of the relevant TYACNCG. The reviewers should check that it fulfils the features above.

The reviewers should enquire as to the distribution process.

Note: The TYACNCG should, for compliance with their relevant measure, produce the pathway and the NSSG, for compliance with this measure, should agree to abide by it, add local contact points and distribute it.

The TYA Pathway for Follow Up on Completion of First Line Treatment

The NSSG should agree, with the chair of the relevant TYACNCG the TYACN patient pathway for follow up on completion of first line treatment including any features specific to the NSSG’s cancer site and their host adult cancer network and incorporating their relevant MDT contact numbers.

The NSSG should distribute the pathway to the lead clinicians of the MDTs of their...
cancer site in their host cancer network.

Compliance:
The pathway, agreed by the Chair of the NSSG and the chair of the relevant TYACNCG. The reviewers should check that it fulfils the features above.
The reviewers should enquire as to the distribution process.

Note:
The TYACNCG should, for compliance with their relevant measure, produce the pathway and the NSSG, for compliance with this measure, should agree to abide by it, add local contact points and distribute it.

Agreed Named Members and Agreed Terms of Reference for NSSG

There should be a single NSSG, having a membership fulfilling the following:

- the MDT lead clinician from each MDT in the network;
- at least one nurse core member of a MDT in the network;
- there should be a named chair who should be a core member of one of the associated MDTs;
- two user representatives;
- one of the NHS employed members of the NSSG should be nominated as having specific responsibility for users' issues and information for patients and carers;
- a NSSG member responsible for ensuring recruitment into clinical trials and other well designed studies is integrated into the function of the NSSG;
- named secretarial/administrative support.

There should be terms of reference agreed for the NSSG which include:

- the provision of clinical opinion on issues relating to UGI cancer for the network;
- the development of patient pathways and clinical guidelines;
- the co-ordination and consistency across the network for cancer policy, practice guidelines, audit, research and service development;
- consulting with the relevant 'cross cutting' network groups on issues involving chemotherapy, cancer imaging, histopathology and laboratory investigation and specialist palliative care; and with the head of service on issues involving radiotherapy.

Notes:

- There may be additional agreed members and attendance at an individual meeting need not be limited to the agreed members.
- If the local user group do not wish, or are unable to nominate a user representative, but there is an agreed mechanism for obtaining user advice then the measure will be deemed to have been complied with.
- There may be additional points in the agreed terms of reference. Recommendations found in appendix 2.

The NSSG should agree, with CCGs, a policy that their primary care practitioners will refer all patients defined by the 'urgent, suspicious of cancer' guidelines for UGI cancer to the contact point of a single named diagnostic or diagnostic/local care team.

Compliance:
The named members and terms of reference agreed by the Chair of the NSSG.

Primary Care Referral Policy

The NSSG should agree, with the CCGs, a policy that their primary care practitioners will refer all patients defined by the 'urgent, suspicious of cancer' guidelines for UGI cancer to the contact point of a single named diagnostic or diagnostic/local care team.

Compliance:
The written policy agreed by the Chair of the NSSG and CCG leads.

Network Configuration of Teams
The NSSG should agree, in consultation with the lead clinicians of each trust in the network, the configuration of the teams in the network.

The configurations should conform to one or other of those described in the introduction to UGI measures.

The diagnostic and diagnostic/local care teams should be named with their host hospitals and trusts and referring individual practices.

Notes:

This includes specialist teams acting in their capacity as local teams for their own local (secondary) catchment population.

The principles of a given primary care practice stating that patients will be referred to a given MDT is not intended to restrict patient or GP choice. A rational network of local and specialist MDTs can only be developed if i) there is an agreement on which MDT the patients will normally be referred to and ii) the resulting referral catchment populations are counted once, for planning purposes. It is accepted that individual patients will, on occasion, be referred to different teams depending on specific circumstances.

The referring catchment population of each named diagnostic or diagnostic/local care team should be specified. No individual primary care practice's population should count more than once.

The specialist teams should be named with their host hospital and trust.

The referral populations should be specified, this should be a minimum of 1 million for OG teams and 2 million for pancreatic teams. The population should be estimated, in each case, from the catchment populations of their respective referring diagnostic and diagnostic/local care teams.

Compliance: The names, locations and types of team agreed by the Chair of the NSSG and the relevant MDT lead clinicians.

REFERRAL GUIDELINES BETWEEN TEAMS

In view of (a) the various possible configurations of service and (b) the need to have agreed the particular group of configurations for the network, the responsibility for review purposes for referral guidelines lies with the lead clinician of the MDT and the Chair of the NSSG. For compliance, the NSSG, should produce agreed guidelines and the individual MDT, for their compliance, should agree to them.

Network Agreed Referral Guidelines Between Teams

The NSSG should agree referral guidelines for each named team in the network, complying with the contents specified in the 'referral guidelines between teams' measures for each team type.

Notes:

- Diagnostic teams and teams dealing with local care may make referrals to specialist teams in another network and specialist teams may receive referrals from another network, all on the grounds of minimum catchment populations.
- These agreed arrangements should be stated, naming teams and their host hospitals as in the referral guidelines in topic 2F.

Compliance: The referral guidelines for each named team in the network, agreed by the Chair of the NSSG.
Introduction

The diagnostic process should be carried out by a defined diagnostic team which liaises with primary care over the "guidelines for urgent referral for suspected cancer". The team refers cancer patients to other teams providing local care or specialist care.

It can be foreseen that some small hospitals far from other services would host a diagnostic team in isolation. However, by applying an underlying principle of the IOG upper GI tract guidance, i.e. consolidation of services for a group of relatively rare cancers, then in most instances the diagnostic team will also offer local care to the relevant local patients. Following the same principle and the fact that both the diagnostic process and local care will largely be undertaken by the same personnel, it is recommended local care teams should not exist in isolation from the diagnostic process. Therefore the measures refer to diagnostic and combined diagnostic/local care teams, the latter comprising of the diagnostic team with some modifications. For the situation where a population is served by a local hospital hosting a specialist team, there are different arrangements for the diagnostic process and local care delivery which are described later.

UPPER GI DIAGNOSTIC TEAM AND DIAGNOSTIC/LOCAL CARE TEAM

This set of measures should be applied to both types of team, except where more specific applications are stated for certain measures.

When is a Team a Team and when is it not a Team?

The measures review a variety of aspects of the team, both structure and function, but the key question, which underlies all this, is who exactly constitutes the MDT, from the point of view of the peer review? Which group of people should be put forward for review against these measures, and who is it who is held compliant or not compliant? This is best answered from the patient's point of view. If you were a patient, who would you consider to be your MDT? Primarily it is that group of people of different health care disciplines, which meets together at a given time (whether physically in one place, or by video or tele-conferencing) to discuss a given patient and who are each able to contribute independently to the diagnostic and treatment decisions about the patient. They constitute that patient's MDT.

The way the MDT meeting itself is organised is left to local discretion such that different professional disciplines may make their contributions at different times, without necessarily being present for the whole meeting, in order to prevent wastage of staff time. The key requirement is that each discipline is able to contribute independently to the decisions regarding each relevant patient. The specific situation where a separate 'diagnostic' meeting of a particular subset of the MDT membership, filters out cases with benign conditions, is dealt with where relevant, by a specific measure. For some cancer types the IOG has laid down detailed requirements over how the diagnostic process should be incorporated into the MDT system and this has also been translated into the measures where applicable.

Two or more groups of people who may have declared an alliance to form a so-called 'combined' MDT but who do not all meet together to collectively contribute to the decisions on a given patient as specified above, do not constitute an MDT from the point of view of peer review. Such alliances have been attempted in order to achieve, for instance, a minimum caseload or catchment population. This is not appropriate. Each separate group, meeting as specified above, should be reviewed separately against such criteria.

In general the measures should be applied to that defined group, but there are some functions for which MDTs may combine in a way which is appropriate. Then, the evidence put forward to demonstrate their compliance with the relevant measures may serve as common evidence across the MDTs but it is applied separately and compliance is awarded separately to each team.

The main examples of this are as follows:

- a combined operational policy meeting but the policies are agreed on behalf of each MDT by its lead clinician;
• network-wide clinical, referral, imaging and pathology guidelines, but each MDT agrees to abide by them;
• the same network-wide project for network audit, but each MDT agreeing to participate;
• a common minimum dataset, but each MDT agrees to collect its portion of it;
• a network list of approved trials but each MDT agrees to enter patients;
• an individual health professional being a member of more than one MDT, but a particular defined and named set of people make up a given MDT.

As well as meeting to make the combined multidisciplinary decisions about patients, the members of some types of MDTs are required by the measures to carry out another key function in company with other specified personnel. Thus, some of the more complex surgical procedures should all be performed by the same group of professionals - surgeon, anaesthetist and skilled theatre and aftercare staff. This is ensured by requiring services to be organised for that MDT so that all cases of a given procedure are performed in the same hospital. The people will largely be a different set of people from those who meet to make the diagnostic and treatment decisions (the MDT as defined as in the measures) but they will directly relate to that MDT and be specified by it, because at least one key functionary, the surgeon, will be a core member of that MDT.

In requiring all the complex procedures to be performed in the same hospital of the MDT, this ties in the referral catchment population of the MDT to that hospital. This provides a direct link between the referring catchment population for MDT discussion, and the treatment caseload of the treatment team and its hospital facilities.

### MEASURE DETAILS & DEMONSTRATION OF COMPLIANCE

#### MDT STRUCTURE

The responsibility, for review purposes, for measure 11-2F-101 lies with the lead clinician of the host trust.

**Lead Clinician and Core Team Membership**

**11-2F-101** There should be a single named lead clinician for the MDT who should then be a core team member.

The lead clinician of the MDT should have agreed the responsibilities of the position with the lead clinician of the host trust.

*Note:*

_The role of lead clinician of the MDT should not of itself imply chronological seniority, superior experience or superior clinical ability._

The MDT should provide the names of core team members for named roles in the team.

The core team specific to the UGI cancer diagnostic or diagnostic/local care team should include:

- one or more clinicians (physicians or surgeons) specialising in gastroenterology;
- endoscopist of any discipline, who could be one of the other team members;
- histopathologist;
- radiologist;
- clinical oncologist;
- medical oncologist (where the responsibility for chemotherapy is not undertaken by the clinical oncologist core member);
- upper GI nurse specialist;
- MDT co-ordinator/secretary;
- a core member of the specialist palliative care team.
- an NHS-employed member of the core or extended team should be nominated as having specific responsibility for users issues and information for patients and carers;
- a member of the MDT nominated as the person responsible for ensuring that recruitment into clinical trials and other well designed studies is integrated into the MDT.

*Notes:*

- _Each clinical core member should have sessions specified in the job plan for the_
### Measure Details & Demonstration of Compliance

**Care of patients with upper GI cancer and attendance at MDT meetings.**

- Where a medical specialty is referred to the core team member should be a consultant. The cover for this member need not be a consultant. Where a medical skill rather than a specialty is referred to, this may be provided by one or more of the core members or by a career grade non-consultant medical staff member.
- The medically qualified core member(s) depend on the cancer site of the MDT.
- The co-ordinator/secretary role needs different amounts of time depending on team workload. See [appendix 2](#) for an illustration of the responsibilities of this role. The co-ordinator and secretarial roles may be filled by two different named individuals or the same one. It need not occupy the whole of an individual's job description.
- There may be additional core members agreed for the team besides those listed above.

**Compliance:**

- Named lead clinician for the MDT agreed by the lead clinician of the host trust.
- The written responsibilities agreed by the lead clinician of the MDT and lead clinician of the host trust.

**Note:**

- See [appendix 2](#) for an illustration of the responsibilities of this role.
- Name of each core team member with their role, agreed by the lead clinician of the MDT.

**Note:**

The reviewers should record in their reports each case where the post(s) needed to provide the minimum core membership for a given listed role in the measure is unfilled or non-existent or existing posts cannot provide the service. This does not refer to mere holiday or sickness absence, or less than 67% attendance, and it refers only to the core member roles listed in the measure, not additional roles that the MDT has decided locally to include as core members, e.g. from the list in the 'extended MDT' measure. The reviewers should identify particular missing roles and identify the particular MDT in the report.

The responsibility, for review purposes, for the subsequent measures lies with the lead clinician of the MDT.

#### Level 2 Practitioners for Psychological Support

**11-2F-102**

At least one clinical core member of the team should have completed the training necessary to enable them to practice at level 2 for the psychological support of cancer patients and carers.

**Notes:**

- This measure applies only to those disciplines which have direct clinical contact and which are named in the list in the MDT structure measure for core membership.
- The relevant discipline include medical, surgical, nursing and allied health professionals.
- If the MDT has one or more clinical core members who are trained to level 3 or 4, the team is deemed to be automatically compliant with this measure.
- The definition of the levels may be found in appendix 1 of the Psychological support measures.

**Compliance:**

- The named member.
- Written confirmation of completion of training agreed by the lead clinician of the MDT.

#### Support for Level 2 Practitioners

**11-2F-103**

The level 2 practitioner(s) should receive a minimum of 1 hours clinical supervision by a level 3 or level 4 practitioner per month.

**Compliance:**

- Reviewers should enquire to ascertain that this is taking place.

#### Team Attendance at NSSG Meetings

**11-2F-104**

The lead clinician of the MDT or representative should attend at least two thirds of the NSSG meetings.
### MEASURE DETAILS & DEMONSTRATION OF COMPLIANCE

**Compliance:** The attendance record of the NSSG.

#### MDT Meetings

<table>
<thead>
<tr>
<th>Measure</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>11-2F-105</td>
<td>The team should hold its meetings at least weekly, record core members' attendance and have a written procedure governing how to deal with referrals which need a treatment planning decision before the next scheduled meeting. (Guidance only - e.g. letters, emails or phone calls between certain specified members, retrospective discussion at the next scheduled meeting).</td>
</tr>
</tbody>
</table>

**Compliance:** Attendance records of the meetings.

#### MDT Agreed Cover Arrangements for Core Member

<table>
<thead>
<tr>
<th>Measure</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>11-2F-106</td>
<td>The MDT should agree named cover arrangements for each core member (see 11-2F-101).</td>
</tr>
</tbody>
</table>

**Notes:**

- This refers to the nominating of staff who should in general be expected to provide cover for core members e.g. a specialist trainee on a consultant's team or core members of the same discipline providing cover for each other. It does not refer to the member having to provide a person to cover for each and every absence. This aspect is dealt with by the attendance measure below.
- Where a medical specialty is referred to the cover for a core member need not be a consultant, but if not should be a specialist trainee or non-consultant career grade.

**Compliance:** Written arrangements agreed by the lead clinician of the MDT.

#### Core Member (or cover) Present for 2/3 of Meetings

<table>
<thead>
<tr>
<th>Measure</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>11-2F-107</td>
<td>Core members or their arranged cover (see measures 11-2F-101 and 11-2F-106) should attend at least two thirds of the number of meetings.</td>
</tr>
</tbody>
</table>

**Compliance:** Attendance record of the MDT.

The reviewers should identify the particular roles where attendance is below the requirements of this measure.

**Note:**

The intention is that core members of the team should be personally committed to it, reflected in their personal attendance at a substantial proportion of meetings, not relying instead on their cover arrangements. Reviewers should use their judgement on this matter and should highlight in their report where this commitment is lacking.

---

### OPERATIONAL POLICIES

#### Annual Meeting to Discuss Operational Policy

<table>
<thead>
<tr>
<th>Measure</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>11-2F-108</td>
<td>Besides the regular meetings to discuss individual patients, the team should meet at least annually to discuss, review, agree and record at least some operational policies.</td>
</tr>
</tbody>
</table>

**Compliance:** Written confirmation of at least one meeting agreed by the lead clinician of the MDT to illustrate the recording of at least some operational policies.

#### Policy for All New Patients to be Reviewed by MDT

<table>
<thead>
<tr>
<th>Measure</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>11-2F-109</td>
<td>There should be an operational policy for the team whereby it is intended that all new cancer patients will be reviewed by a multidisciplinary team for discussion of initial treatment plan. The policy should specify at what other stages in the patient pathway patients are referred back for discussion.</td>
</tr>
</tbody>
</table>

**Compliance:** The written operational policy agreed by the lead clinician of the MDT.
The MDT should have agreed a policy whereby all patients diagnosed with UGI cancer are discussed with a member of the relevant specialist team prior to referral to the specialist team or prior to proposed local care. The date at which the discussion took place should be recorded in the case notes.

**Compliance:** The written policy, agreed by the lead clinician of the MDT.

The MDT should have agreed a policy whereby after a patient is given a diagnosis of cancer, the patient's general practitioner (GP) is informed of the diagnosis by the end of the following working day.

The MDT should have completed an audit against the policy of the timeliness of notification to general practitioners of the diagnosis of cancer.

**Compliance:** The written policy agreed by the lead clinician of the MDT.
The written results of the audit.

Follow up arrangements between the specialist team and the referring diagnostic/local care team(s) may vary locally according to circumstances, but written follow up guidelines should be agreed between the specialist team and the referring team(s).

The arrangements should include those for patients who are referred to the specialist team but are found to be unsuitable for specialist care.

**Compliance:** Follow up guidelines agreed by the lead clinician of the specialist MDT and the Chair of the NSSG.

There should be an operational policy whereby a single named key worker for the patient's care at a given time is identified by the MDT for each individual patient and the name and contact number of the current key worker is recorded in the patient's case notes. The responsibility for ensuring that the key worker is identified should be that of the nurse MDT member(s).

The policy should have been implemented for patients who came under the MDT's care after publication of these measures and who are under their care at the time of the peer review visit.

**Notes:**
- For information: according to the NICE palliative care guidance, a key worker is a person who, with the patient's consent and agreement, takes a key role in co-ordinating the patient's care and promoting continuity e.g. ensuring the patient knows who to access for information and advice. This is not intended to have the same connotation as the key worker in social work.
- It may be necessary to agree a single key worker across both a cancer site specific MDT and the specialist palliative care MDT for certain patients.

**Compliance:** The written policy agreed by the lead clinician of the MDT.

Reviewers should spot check some of the relevant patients' case notes.

The core histopathology member(s) of the MDT should be taking part in an EQA scheme, either a specialist scheme for the cancer site(s) of the team or a general EQA scheme which has a section covering the cancer site(s) of the team.
MEASURE DETAILS & DEMONSTRATION OF COMPLIANCE

Compliance: Documentary evidence to show that they are taking part in a relevant EQA.

Note: Their actual performance against the requirements of the EQA is not subject to peer review.

MDT NURSE SPECIALIST MEASURES

Introduction

Why are there currently "nursing measures" for MDTs, but no similar requirements for other MDT members?

The modern change to MDT working has created and then highly developed the specific role of nurse MDT member with its related activities which, in full measure, go to make up the role of the cancer nurse specialist. The roles of the medical specialties in the MDT have not been so profoundly influenced or so extensively developed by their MDT membership itself compared to that of the MDT nurse specialist. The role definitions and training requirements of nurse MDT members are not very well "officially" established outside the MDT world in contrast to the well defined medical specialties with their formal national training requirements (e.g. there were UGI surgeons and palliative care physicians before there were established UGI MDTs and specialist palliative care teams). Therefore, a particularly strong need was perceived for using the measures to define more clearly the role of the nurse specialist and to set out minimum training requirements for nursing input into MDTs. This is in order to establish these roles more firmly in the NHS infrastructure and to avoid the situation where MDTs can comply with measures by having generalist nurses who "sit in" on MDT meetings and sign attendance forms but play no defining role in the team's actual dealings with its patients.

Core Nurse Member Completed Specialist Study

Each core nurse specialist should have successfully completed a programme of study in their specialist area of nursing practice, which has been accredited for at least 20 credits at first degree level or equivalent.

Compliance: Confirmation of successful completion of the course/module.

Core Nurse Responsibilities

The MDT should have agreed a list of responsibilities, with each of the core nurse specialists of the team, which includes the following:

- contributing to the multidisciplinary discussion and patient assessment/care planning decision of the team at their regular meetings;
- providing expert nursing advice and support to other health professionals in the nurse's specialist area of practice;
- involvement in clinical audit;
- leading on patient and carer communication issues and co-ordination of the patient pathway for patients referred to the team - acting as the key worker or responsible for nominating the key worker for the patient's dealings with the team.
- ensuring that results of patients' holistic needs assessment are taken into account in the decision making;
- contributing to the management of the service (see note below);
- utilising research in the nurse's specialist area of practice.

Notes:

- "Management" in this context does not mean clerical tasks involving the documentation on individual patients i.e. this responsibility does not overlap with the responsibility of the MDT co-ordinator.
- A list of responsibilities containing all the elements in this measure and the previous measure would encompass all of the four domains of specialist practice required for the role of cancer nurse specialist.
- Additional responsibilities may be agreed.

Compliance: The list of responsibilities agreed by the lead clinician of the MDT and the core nurse specialist(s).
### Attendance at National Advanced Communication Skills Training Programme

**11-2F-117** At least those core members of the team who have direct clinical contact with patients should have attended the national advanced communications skills training.

**Notes:**
- *This measure applies only to those disciplines which have direct clinical contact and which are named in the list in the MDT structure measure for core membership.*
- *Also, it applies only with regard to members which are in place i.e. if a team lacks a given core member from that list, it should still be counted as compliant with this measure provided those members which are in place, comply.*
- *The relevant disciplines include medical, surgical, nursing and allied health professionals.*
- *The reviewers should record which core members of those relevant are non-compliant.*

**Compliance:**
Written confirmation of the MDT members who have attended the national advanced communication skills training programme.

### Extended Membership of MDT

**11-2F-118** The MDT should provide the names of members of the extended team for named roles in the team.

**Notes:**
- *The MDT may choose to have no extended team. This should be stated in writing.*

**Compliance:**
- Name of each extended team member with their role, or written agreement to have no extended team, agreed by the lead clinician of the MDT.
- Name of each extended team member and their role, agreed by lead clinician of the MDT.

### Extended Membership to include specialist palliative care representative and dietician

**11-2F-119** If they are not already offered as core team members, the named team for the extended MDT should include:

- core member of the specialist palliative care team;
- dietician.

**Note:**
- *The MDT may wish to name additional extended team members.*
- *Although there is not a requirement to have a named social worker as part of the extended team, there should be arrangements in place to access a social worker when required.*

**Compliance:**
Name of each extended team member and their role, agreed by lead clinician of the MDT.
## PROVIDING PATIENT CENTRED CARE

### Patient Permanent Consultation Record

**11-2F-120** The MDT should be giving patients the opportunity of a permanent record or summary of at least a consultation between the patient and the doctor when the following are discussed:

- diagnosis;
- treatment options and plan;
- relevant follow up (discharge) arrangements.

**Note:**

*The MDT may, in addition, offer a permanent record of consultations undertaken at other stages of the patient's journey.*

*The record of consultation should identify areas discussed during consultation and include a diagram where appropriate which supports the consultation discussion.*

*The consultation record provides a permanent summary of the discussion between the doctor and the patient and should always be offered to the patient unless specifically declined by the patient; A record should be kept in the notes.*

**Compliance:**

The reviewers should enquire of the working practice of the team and see examples of anonymised records given to patients.

**Note:**

*It is recommended that they are available in languages and formats understandable by patients including local ethnic minorities and people with disabilities. This may necessitate the provision of visual and audio material.*

### Patient Experience Exercise

**11-2F-121** The MDT should have undertaken (or be undertaking) an exercise during the previous two years prior to review or completed self-assessment to obtain feedback on patients' experience of the services offered.

The exercise should at least ascertain whether patients were offered:

- a key worker;
- assessment of their physical, emotional, practical, psychological and spiritual needs (holistic needs assessment);
- the MDTs information for patients and carers (written or otherwise);
- the opportunity of a permanent record or summary of a consultation at which their treatment options were discussed.

**Notes:**

- *The exercise may consist of a survey, questionnaire, focus group or other method.*
- *There may be additional items in the exercise. It is recommended that other aspects of patient experience are covered.*

The exercise should have been presented and discussed at an MDT meeting and the team should have implemented at least one action point arising from the exercise.

**Compliance:**

The results of the exercise.

A report for the action taken.

### Provision of Written Patient Information

**11-2F-122** The MDT should provide patients and carers written material which includes:

- information specific to that MDT about local provision of the services offering the treatment for that cancer site;
- information about patient involvement groups and self-help groups;
MEASURE DETAILS & DEMONSTRATION OF COMPLIANCE

• information about the services offering psychological, social and spiritual/cultural support, if available;
• information specific to the MDT's cancer site or group of cancers about the disease and its treatment options (including names and functions/roles of the team treating them).
• information about services available to support the effects of living with cancer and dealing with its emotional effects

It is recommended that the information and its delivery to patients and carers follow the principles of the NHS Information Prescription project.

(www.informationprescription.info).

Notes:
The named extended team for the MDT should include:

• The information prescription should be tailored to the patients/carers needs based on an information needs assessment. Information may be generated and dispensed outside of the clinic environments within an information centre where a clear operational policy between the clinic and information centre is in place which identifies how clinic records are updated and that facilitates and resources within the information centre are appropriate to providing such a service
• The information prescription should be composed of information from the national pathways supplemented with national and local accredited information

Compliance: The written, (visual and audio if used - see note below) material.
Notes:
It is recommended that it is available in languages and formats understandable by patients including local ethnic minorities and people with disabilities. This may necessitate the provision of visual and audio material.
For the purpose of self-assessment the team should confirm the written information which is routinely offered to patients.

DIAGNOSTIC REFERRAL DECISION

The following measure applies to the diagnostic/local care team only.

Agree and Record Individual Patient Diagnosis and Referral

11-2F-123
The core MDT at their regular meetings should agree and record patients' diagnosis and subsequent referral. The record should include:

• the identity of patients discussed;
• the diagnosis, at the time of making the referral decision;
  (i) benign
  (ii) malignant (with histological confirmation)
  (iii) malignant (without histological confirmation)
• type of cancer (pancreatic or OG);
• referral decision (which should be updated if necessary after the discussion of the case with a specialist team member);
  (i) retained for local care by diagnostic/local care team
  (ii) to which specialist team (named if more than one is possible from the relevant configuration)
• in the case of patients referred for specialist care to another team in the network, the team to which they are referred should be named.
MEASURE DETAILS & DEMONSTRATION OF COMPLIANCE

Compliance: Anonymised examples of the record of a meeting and individual anonymised treatment plans.

Notes:
Only exactly what is required in the list above is necessary for evidence.
Detailed minutes of the content of discussions over patients are not required for evidence.
For review purposes patient specific information should be anonymised.
It is recommended that this essential information is recorded on an MDT proforma as well as in individual patients’ notes.

CLINICAL GUIDELINES

The responsibility for review purposes for clinical guidelines lies with the lead clinician of the MDT and Chair of the NSSG. For compliance, the NSSG in consultation with the MDTs, should produce the agreed network-wide clinical guidelines. The individual MDT for their compliance with this measure should agree to them.

MDT Agreement to Network Clinical Guidelines for the Management of Upper GI Cancer

11-2F-124

a) The MDT should agree network-wide clinical guidelines for patients diagnosed with UGI cancer with the NSSG. The guidelines should state the parameters of disease stage and patient fitness which determine when each of the treatments/ procedures classified as local care or specialist care, in the introduction, are indicated.

b) The diagnostic/local care team should agree with each of its specialist teams and the NSSG:
• which of the treatments/procedures classified as local care in the introduction may be delivered by the local care team, subject to each case being discussed with a member of the specialist team prior to the proposed treatment.

Note:
A diagnostic-only team would usually refer all patients directly to a specialist team.

Compliance: The clinical guidelines agreed by the lead clinician of the diagnostic/local care team and the Chair of the NSSG.

REFERRAL GUIDELINES BETWEEN TEAMS

The format of these measures is specific to UGI cancer. In view of (a) the various possible configurations of the service and (b) the need to have agreed the particular group of configurations for the network, the responsibility for review purposes for referral guidelines lies with the lead clinician of the MDT, the Chair of the NSSG. For compliance the NSSG should produce agreed guidelines and the individual MDT for their compliance should agree them.

The following measure applies to the diagnostic team only.

MDT Agreement to Network Referral Guidelines (diagnostic)

11-2F-125

The MDT should agree referral guidelines which include the following:
• to what extent and in what circumstances the diagnostic team may further investigate a patient after the diagnosis of malignancy and before referral to other teams;
• that patients who need specialist care are referred to teams offering specialist care with the names of the teams and their host hospitals;
• that patients who need local care are referred to a team offering local care with the name of the team and their host hospitals.

Notes:
• Specialist care and local care are defined in the introduction to the UGI measures.
• It is strongly recommended that when patients are referred for care to another team all members of the referring MDT refer patients with a given cancer type to the same
## MDT Agreement to Network Referral Guidelines (diagnostic/local care)

**11-2F-126**

The MDT should agree referral guidelines which include the following:

- to what extent and in what circumstances the diagnostic team may further investigate a patient after the diagnosis of malignancy and before referral to other teams;
- that patients who need specialist care are referred to teams offering specialist care with the names of the teams and their host hospitals.

**Notes:**

- Specialist care and local care are defined in the introduction to the UGI measures.
- It is strongly recommended that when patients are referred for care to another team all members of the referring MDT refer patients with a given cancer type to the same named team.

**Compliance:** The referral guidelines agreed by the lead clinician of the MDT and Chair of the NSSG.

**Note:**

Diagnostic and diagnostic/local care teams may make referrals to specialist teams in another network on the grounds of minimum catchment populations. The referral guidelines should then name the relevant teams in the other (receiving) network, with their host hospitals.

---

## IMAGING GUIDELINES

The responsibility for review purposes for imaging guidelines lies with the lead clinician of the MDT and Chair of the NSSG. For compliance, the NSSG in consultation with the MDTs, should produce the agreed network-wide imaging guidelines. The individual MDT for their compliance with this measure should agree to them.

### MDT Agreement to Network Imaging Guidelines

**11-2F-127**

The MDT should agree imaging guidelines for diagnosis and review. The guidelines should address:

- imaging modalities;
- their specific indications.

**Compliance:** The imaging guidelines agreed by the lead clinician of the MDT and the Chair of the NSSG.
**PATHOLOGY GUIDELINES**

The responsibility for review purposes for pathology guidelines lies with the lead clinician of the MDT and Chair of the NSSG. For compliance, the NSSG in consultation with the MDTs, should produce the agreed network-wide pathology guidelines. The individual MDT for their compliance with this measure should agree to them.

**MDT Agreement to Network Pathology Guidelines**

11-2F-128 The MDT should agree pathology guidelines for diagnosis and review. The guidelines should address:

- laboratory and histopathology/histochemical investigations;
- their specific indications.

**Compliance:** The pathology guidelines agreed by the lead clinician of the MDT and the Chair of the NSSG.

**Agreed Collection of Minimum Dataset**

11-2F-129 The MDT should be recording its agreed part of the MDS, according to the network data collection specification, in an electronically retrievable form.

**Compliance:** Anonymised examples of the recorded data for individual patients.

**Note:**
*For the purpose of self assessment, the team should confirm that they started to record the MDS.*

**NETWORK AUDIT**

**Introductory Notes**

For review purposes a network audit project is an audit project related to the cancer site or sites of the NSSG and the activities of its MDTs. The same project should be carried out by all MDTs for that cancer site in the network, each team’s results being separately identified. The individual MDTs, for compliance with their relevant MDT measure, should agree to participate in the audit. See appendix 1 for audit.

**Network Audit**

11-2F-130 The MDT should agree to participate in the network audit project agreed by the NSSG. The MDT should annually review the progress of the project or present the results of the completed network audit project to the NSSG for discussion at one of their meetings.

**Notes:**
*For MDTs which have previously been peer reviewed the project should have been completed since that previous peer review.*

**Compliance:** The audit agreed by the lead clinician of the MDT and the Chair of the NSSG. Written confirmation of review of progress of audit sufficient to show compliance with the measure.

**Discussion of Clinical Trials**

11-2F-131 The MDT should produce a report at least annually on clinical trials, for discussion with the NSSG. The report should include:

- Details of the MDT’s trials portfolio including the extent of local provision of the national portfolio.
- The MDT’s recruitment to the portfolio, including the extent of delivery against the locally agreed timescales and targets.
- The MDT’s programme for improvement for the above, as proposed to the NSSG.

The MDT should agree a final programme for improvement at the NSSG discussion meeting.

**Note:**
MEASURE DETAILS & DEMONSTRATION OF COMPLIANCE

For compliance with this measure the MDT should produce a proposed programme for improvement and, at the discussion with the NSSG, settle on a mutually agreed programme between the participants of the meeting.

In addition, applicable only to MDTs dealing with the following cancer sites:

- Leukaemia
- Lymphoma
- Germ cell malignancy
- Bone and/or soft tissue sarcoma
- Brain and CNS malignancy
- Malignant melanoma

The MDT should produce a report on clinical trials, covering the above points, for TYA patients, for discussion at the teenage and young adults’ cancer network co-coordinating group (TYACNCG).

The MDT should agree a final programme for improvement for TYA clinical trials with the TYACNCG.

Note:

The TYACNCG’s current list of trials and studies suitable for TYAs may not include any of those malignancies dealt with by the MDT under review, in which case this is not applicable for the current assessment in question.

Compliance:

The report, agreed by the lead clinician of the MDT. The reviewers should check that the contents fulfil the points above.

The programme for improvement, agreed by the lead clinician of the MDT and the clinical lead for the cancer research network.

Where relevant, the clinical trials report for TYA patients, agreed by the lead clinician of the MDT, and the programme for improvement agreed by the lead clinician of the MDT, Chair of the TYACNCG and the clinical lead for the cancer research network.
Joint Treatment Planning for TYAs

For each patient in the TYA age group, the MDT should agree the following decisions with the TYA MDT and record them as part of that patient's joint treatment planning decision:

- the multidisciplinary treatment planning decision (i.e. to which modality(s) of treatment-surgery, radiotherapy, chemotherapy, biological therapy or supportive care, or combinations of the same, they are to be referred to for consideration);
- the named consultant in charge of each modality of definitive treatment and the named person in charge of organising arrangements for the age-appropriate support and care environment including those when the treatment is delivered outside the PTC facility.

For those in the age range 19 to the end of their 24th birthday, the MDT should record the choice of treatment location, made by the patient, in particular, whether it is the TYA facility or which of the named designated hospitals for TYAs.

Notes:

*Patients in the age range 16 to the end of their 18th birthday should be treated in the PTC.*

*The date of joint agreement to the planning and of the patient's choice of treatment place may be later than the date of the initial treatment planning discussion by the MDT.*

Compliance: The reviewers should ask to see examples of the treatment planning decision record of patients from the TYA age group. Evidence of joint agreement should be by individual TYA patient decision records of the site-specific MDT being authorised by a core member of the TYA MDT.

Note:

*If the MDT has had no such patients referred since the last assessment/review this part of the measure is considered to have been complied with. The overall compliance depends then, only on the non-TYA aspects of this measure.*
Introduction

Specialist care should be provided by defined and separate specialist teams for OG cancer and pancreatic cancer. With reference to the team's catchment population, the 1 million minimum for OG means that most cancer centres and some larger cancer units will potentially be able to host a team. Some smaller centres and even some smaller networks will not be able to have a team however. The 2 million population minimum for pancreatic cancer means that no cancer units and only some centres will be able to have a team. Also the 2 million minimum means that currently, in England, no network on the basis of its own catchment population will be able to have more than one pancreatic team.

A further principle in the IOG upper GI guidance is that the meetings, surgical operations and acute post-operative care (including HDU and ITU) of a given specialist team should all take place in one hospital. This principle, together with the minimum catchment populations and the principle of consolidation of services for a group of relatively rare cancers have the following important implications:

- in a given single locality which has a specialist OG team, it should be the only OG team for that locality;
- in a given locality which has a specialist pancreatic team it should be the only pancreatic team for that locality.

The exact boundaries of what constitutes a team and what does not, as outlined in the introduction to MDTs is especially important here. This set of measures should be applied to both types of team (OG and pancreatic).

When is a Team a Team and When is it not a Team?

The measures review a variety of aspects of the team, both structure and function, but the key question, which underlies all this, is who exactly constitutes the MDT, from the point of view of the peer review? Which group of people should be put forward for review against these measures, and who is it who is held compliant or not compliant? This is best answered from the patient's point of view. If you were a patient, who would you consider to be your MDT? Primarily it is that group of people of different health care disciplines, which meets together at a given time (whether physically in one place, or by video or tele-conferencing) to discuss a given patient and who are each able to contribute independently to the diagnostic and treatment decisions about the patient. They constitute that patient's MDT.

The way the MDT meeting itself is organised is left to local discretion such that different professional disciplines may make their contributions at different times, without necessarily being present for the whole meeting, in order to prevent wastage of staff time. The key requirement is that each discipline is able to contribute independently to the decisions regarding each relevant patient. The specific situation where a separate 'diagnostic' meeting of a particular subset of the MDT membership, filters out cases with benign conditions, is dealt with where relevant, by a specific measure. For some cancer types the IOG has laid down detailed requirements over how the diagnostic process should be incorporated into the MDT system and this has also been translated into the measures where applicable.

Two or more groups of people who may have declared an alliance to form a so-called 'combined' MDT but who do not all meet together to collectively contribute to the decisions on a given patient as specified above, do not constitute an MDT from the point of view of peer review. Such alliances have been attempted in order to achieve, for instance, a minimum caseload or catchment population. This is not appropriate. Each separate group, meeting as specified above, should be assessed separately against such criteria.
In general the measures should be applied to that defined group, but there are some functions for which MDTs may combine in a way which is appropriate. Then, the evidence put forward to demonstrate their compliance with the relevant measures may serve as common evidence across the MDTs but it is applied separately and compliance is awarded separately to each team.

The main examples of this are as follows:

- a combined operational policy meeting but the policies are agreed on behalf of each MDT by its lead clinician;
- network-wide clinical, referral, imaging and pathology guidelines, but each MDT agrees to abide by them;
- the same network-wide project for network audit, but each MDT agreeing to participate;
- a common minimum dataset, but each MDT agrees to collect its portion of it;
- a network list of approved trials but each MDT agrees to enter patients;
- an individual health professional being a member of more than one MDT, but a particular defined and named set of people make up a given MDT.

As well as meeting to make the combined multidisciplinary decisions about patients, the members of some types of MDTs are required by the measures to carry out another key function in company with other specified personnel. Thus, some of the more complex surgical procedures should all be performed by the same group of professionals - surgeon, anaesthetist and skilled theatre and aftercare staff. This is ensured by requiring services to be organised for that MDT so that all cases of a given procedure are performed in the same hospital. The people will largely be a different set of people from those who meet to make the diagnostic and treatment decisions (the MDT as defined as in the measures) but they will directly relate to that MDT and be specified by it, because at least one key functionary, the surgeon, will be a core member of that MDT.

In requiring all the complex procedures to be performed in the same hospital of the MDT, this ties in the referral catchment population of the MDT to that hospital. This provides a direct link between the referring catchment population for MDT discussion, and the treatment caseload of the treatment team and its hospital facilities.
MDT STRUCTURE

The responsibility, for review purposes, for measure 11-2F-201 lies with the lead clinician of the host trust.

Lead Clinician and Core Team Membership

11-2F-201

There should be a single named lead clinician for the specialist UGI MDT who should then be a core team member.

The lead clinician of the MDT should have agreed responsibilities of the position with the lead clinician of the host trust.

Note:
The role of the lead clinician of the MDT should not of itself imply chronological seniority, superior experience or superior clinical ability.

The MDT should provide the names of core team members for defined roles in the team.

The core team specific to the specialist OG MDT should include:

• two or more surgeons;

Note to the above point:
OG or thoracic surgeons may count as core team surgeons.

It is recommended that these are not also hepato-pancreatice-biliary surgeons.

In order to achieve measure 11-2F-214 a 24-hour surgical on-call rota - at least three specialist consultant surgeons per team would be needed.

• physician gastroenterologist;
• clinical oncologist;
• medical oncologist (where the responsibility for chemotherapy is not undertaken by the clinical oncologist core member);
• dietician;
• histopathologist;
• imaging specialist;
• OG nurse specialist;
• a core member of the specialist palliative care team;
• MDT co-ordinator/secretary;
• an NHS-employed member of the core or extended team should be nominated as having specific responsibility for users' issues and information for patients and carers;
• a member of the core team nominated as the person responsible for ensuring that recruitment into clinical trials and other well designed studies is integrated into the function of the MDT;
• at least one of the core team radiologists should be an interventional radiologist;
• there should be a core team member trained in endoscopic ultrasonography.

Notes:

• Each clinical core member should have sessions specified in the job plan for the care of patients with upper GI cancer and attendance at MDT meetings.

• Where a medical specialty is referred to the core team member should be a consultant. The cover for this member need not be a consultant. Where a medical skill rather than a specialty is referred to this may be provided by one or more of the core members or by a career grade non-consultant medical staff member.

• The medically qualified core member(s) depend on the cancer site of the MDT.

• The co-ordinator/secretary role needs different amounts of time depending on team workload. See appendix 2 for illustration of the responsibilities of this role. The co-ordinator and secretarial roles may be filled by two different named individuals or the same one. It may not occupy the whole of an individual's job description.

• The MDT may choose to name additional core members.
### MEASURE DETAILS & DEMONSTRATION OF COMPLIANCE

**Compliance:**
Named lead clinician for the MDT agreed by the lead clinician of the host trust. The written responsibilities agreed by the lead clinician of the MDT and lead clinician of the host trust.

**Note:**
See [appendix 2](#) for an illustration of the responsibilities of this role.

Name of each core team member with their role, agreed by the lead clinician of the host trust.

**Notes:**
The reviewers should record in their assessment each case where the post(s) needed to provide the minimum core membership for a given listed role in the measure is unfilled or non-existent, or existing posts cannot provide the service. This does not refer to mere holiday or sickness absence, or less than 67% attendance, and it refers only to the core member roles listed in the measure, not to additional roles that the MDT has decided locally to include as core members, e.g. from the list in the ‘extended MDT’ measure.

The reviewers should identify the particular missing roles and identify the particular MDT in the report.

---

The responsibility, for review purposes, for the subsequent measures lies with the lead clinician of the MDT.

**Level 2 Practitioners for Psychological Support**

<table>
<thead>
<tr>
<th>Measure Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>11-2F-202</td>
<td>At least one clinical core member of the team should have completed the training necessary to enable them to practice at level 2 for the psychological support of cancer patients and carers.</td>
</tr>
</tbody>
</table>

**Notes:**
- This measure applies only to those disciplines which have direct clinical contact and which are named in the list in the MDT structure measure for core membership.
- The relevant discipline include medical, surgical, nursing and allied health professionals.
- If the MDT has one or more clinical core members who are trained to level 3 or 4, the team is deemed to be automatically compliant with this measure.
- The definition of the levels may be found in [appendix 1](#) of the Psychological support measures.

**Compliance:**
The named member. Written confirmation of completion of training agreed by the lead clinician of the MDT.

**Support for Level 2 Practitioners**

<table>
<thead>
<tr>
<th>Measure Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>11-2F-203</td>
<td>The level 2 practitioner(s) should receive a minimum of 1 hours clinical supervision by a level 3 or level 4 practitioner per month.</td>
</tr>
</tbody>
</table>

**Compliance:** Reviewers should enquire to ascertain that this is taking place.

**Team Attendance at NSSG Meetings**

<table>
<thead>
<tr>
<th>Measure Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>11-2F-204</td>
<td>The lead clinician of the MDT or representative should attend at least two thirds of the NSSG meetings.</td>
</tr>
</tbody>
</table>

**Compliance:** The attendance record of the NSSG.

**MDT Meetings**

<table>
<thead>
<tr>
<th>Measure Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>11-2F-205</td>
<td>The team should hold its meetings at least weekly, record core members’ attendance and have a written procedure governing how to deal with referrals which need a treatment planning decision before the next scheduled meeting. (Guidance only - e.g. letters, emails or phone calls between certain specified members, retrospective discussion at the next scheduled meeting).</td>
</tr>
</tbody>
</table>

**Compliance:** Attendance records of the meetings. Written procedure agreed by the lead clinician of the MDT.
### MDT Agreed Cover Arrangements for Core Member

| 11-2F-206 | The MDT should agree named cover arrangements for each core member (see 11-2F-201).

**Notes:**
- *This refers to the nominating of staff who should in general be expected to provide cover for core members e.g. specialist trainee on a consultant's team or core members of the same discipline providing cover for each other. It does not refer to the member having to provide a person to cover for each and every absence. This aspect is dealt with by the attendance measure below.*
- *Where a medical specialty is referred to the cover for a core member need not be a consultant but if not should be a specialist trainee or non-consultant career grade.*

**Compliance:** Written arrangements agreed by the lead clinician of the MDT.

### Core Member (or Cover) Present for 2/3 of Meetings

| 11-2F-207 | Core members or their arranged cover (see measures 11-2F-201 and 11-2F-206) should attend at least two thirds of the number of meetings.

**Compliance:** Attendance record of the MDT or audit results. The reviewers should identify the particular roles where attendance is below the requirements of this measure.

**Notes:**
- *The intention is that core members of the team should be personally committed to it, reflected in their personal attendance at a substantial proportion of meetings, not relying instead on their cover arrangements. Reviewers should use their judgement on this matter and should highlight in their report where this commitment is lacking.*

**Compliance with this measure also confers compliance with measure 11-2F-206.**

### OPERATIONAL POLICIES

#### Annual Meeting to Discuss Operational Policy

| 11-2F-208 | Besides the regular meetings to discuss individual patients the team should meet at least annually to discuss, review, agree and record at least some operational policies.

**Compliance:** Written confirmation of at least one meeting agreed by the lead clinician of the MDT to illustrate the recording of at least some operational policies.

#### Policy for All New Patients to be Reviewed by MDT

| 11-2F-209 | There should be an operational policy for the team whereby it is intended that all new cancer patients will be reviewed by a multidisciplinary team for discussion of initial treatment plan. The policy should specify at what other stages in the patient pathway patients are referred back for discussion.

**Compliance:** The written operational policy agreed by the lead clinician of the MDT.

#### Policy for Communication of Diagnosis to GP

| 11-2F-210 | The MDT should have agreed a policy whereby after a patient is given a diagnosis of cancer, the patient's general practitioner (GP) is informed of the diagnosis by the end of the following working day. The MDT should have completed an audit against the policy of the timeliness of notification to GPs of a diagnosis of cancer.

**Compliance:** The written policy agreed by the lead clinician of the MDT. The written results of the audit.
The next measure applies to specialist teams referring some cancer types to another specialist team elsewhere in the network or neighbouring network.

**MDT Agreement to Network Specialist Team Policy for Referral Discussion**

**11-2F-211**

The MDT should have agreed a policy whereby all patients diagnosed with the relevant cancer type are discussed with a member of the relevant specialist team prior to referral to that specialist team or prior to proposed local care. The date at which the discussion took place should be recorded in the case notes.

**Compliance:** The policy agreed by the lead clinician of the MDT.

For the following measure, the specialist team should comply with either section (a) or section (b).

**MDT Meeting with Referring Teams/Collaborative Audit**

**11-2F-212**

a) During the year prior to the peer review visit, the specialist MDT should have held a meeting at which at least one core member representative of the specialist team met with at least one core member representative of each of its referring diagnostic, diagnostic/local care teams, and any specialist referring teams, to review all the cases during the previous year diagnosed as having cancer (with or without histological confirmation). At the meeting they should have ascertained whether all cases diagnosed with UGI cancer, relevant to that specialist team, were discussed with them prior to referral or to proposed local care, and whether referrals were consistent with the network clinical and referral guidelines.

b) During the year prior to the peer review visit the specialist team, with any other specialist teams in the network, should have carried out as one of the agreed network audit projects the following:

- an audit of cases (over at least the previous year) diagnosed as having cancer by its referring diagnostic and diagnostic/local care teams (with or without histological confirmation);
- cases referred for specialist care and local care should be audited for consistency with the clinical and referral guidelines;
- the audit should also ascertain whether all cases diagnosed with UGI cancer relevant to that specialist team were discussed with them prior to referral or to proposed local care.

**Notes:**

- The meeting should include a representative of any specialist team referring a certain cancer type to the team in question, whether from within the network or from a neighbouring network.
- For sections a) and b) of this measure, compliance or non-compliance count towards the specialist MDT.
- In section b), completion of the relevant audit project would provide compliance for this measure as well as compliance for part of the network audit.

**Compliance:** Written confirmation, including attendance list of the meeting and the results of the audit as applied to the specialist team in question.

**MDT Agreement to Network Follow Up Guidelines**

**11-2F-213**

Follow up arrangements between the specialist team and the referring diagnostic/local care team(s) may vary locally according to circumstances, but written follow up guidelines should be agreed between the specialist team and the referring team(s).

The arrangements should include those for patients who are referred to the specialist team but are found to be unsuitable for specialist care.

**Compliance:** Follow up guidelines agreed by the lead clinician of the specialist MDT and the Chair of the NSSG.
### 24-Hour On-Call Consultant Specialist Surgical Cover

| 11-2F-214 | There should be 24-hour on-call consultant specialist surgical cover for post operative care.  
**Note:**  
To achieve this measure at least three specialist consultant surgeons per team would be needed.  
**Compliance:** 24-hour on-call rota staffed by core team surgical members. |

### Intensive Care (ITU) and High Dependency Unit (HDU) in Host Hospital

| 11-2F-215 | There should be intensive care (ITU) and high dependency unit (HDU) facilities available in the hospital hosting the specialist MDT.  
**Compliance:** Reviewers to view the facilities.  
**Note:**  
For the purpose of self-assessment the facilities should be confirmed within the teams' operational policy. |

### Single Site Surgery and Post Operative Care

| 11-2F-216 | The treatment planning meetings, operations and acute post-operative care activities of the MDT should all be carried out in the same hospital.  
**Compliance:** Reviewers to view the facilities and enquire of team working arrangements. |

### Operational Policy for Named Key Worker

| 11-2F-217 | There should be an operational policy whereby a single named key worker for the patient's care at a given time is identified by the MDT for each individual patient and the name and contact number of the current key worker is recorded in the patient's case notes. The responsibility for ensuring that the key worker is identified should be that of the nurse MDT member(s).  
The above policy should have been implemented for patients who came under the MDT's care after publication these measures and who are under their care at the time of the peer review visit.  
**Notes:**  
- For information - according to the NICE IOG guidance palliative and supportive care guidance the key worker is a person who, with the patient's consent and agreement, takes a key role in co-ordinating the patient's care and promoting continuity e.g. ensuring the patient knows who to access for information and advice. This is not intended to have the same connotation as the key worker in social work.  
- It may be necessary to agree a single key worker across both a cancer site specific MDT and the specialist palliative care MDT for certain patients.  
**Compliance:** The written policy agreed by the lead clinician of the MDT.  
Reviewers should spot check some of the relevant patients case notes. |

### Histopathology Core Members Participating in EQA Scheme

| 11-2F-218 | The core histopathology member(s) of the MDT should be taking part in an EQA scheme, either a specialist scheme for the cancer site(s) of the team or a general EQA scheme which has a section covering the cancer site(s) of the team.  
**Compliance:** Documentary evidence to show that they are taking part in a relevant EQA.  
**Note:**  
Their actual performance against the requirements of the EQA is not subject to peer review. |
## Introduction

Why are there currently "nursing measures" for MDTs but no similar requirements for other MDT members?

The modern change to MDT working has created and then highly developed the specific role of nurse MDT member, with its related activities which, in full measure, go to make up the role of the cancer nurse specialist. The roles of the medical specialties in the MDT have not been so profoundly influenced or so extensively developed by their MDT membership itself, compared to that of the MDT nurse specialist. The role definitions and training requirements of nurse MDT members are not very well "officially" established outside the MDT world in contrast to the well defined medical specialties with their formal national training requirements (e.g. there were UGI surgeons and palliative care physicians before there were established UGI MDTs and specialist palliative care teams). Therefore, a particularly strong need was perceived for using the measures to define more clearly the role of the nurse specialist and to set out minimum training requirements for nursing input into MDTs. This is in order to establish these roles more firmly in the NHS infrastructure and to avoid the situation where MDTs can comply with measures by having generalist nurses who "sit in" on MDT meetings and sign attendance forms but play no defining role in the team's actual dealings with its patients.

### Core Nurse Member Completed Specialist Study

<table>
<thead>
<tr>
<th>11-2F-219</th>
<th>Each core nurse specialist should have successfully completed a programme of study in their specialist area of nursing practice, which has been accredited for at least 20 credits at first degree level or equivalent.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Compliance:</strong></td>
<td>Confirmation of the certificate of successful completion of the course/module.</td>
</tr>
</tbody>
</table>

### Core Nurse Responsibilities

<table>
<thead>
<tr>
<th>11-2F-220</th>
<th>The MDT should have agreed a list of responsibilities, with each of the core nurse specialists of the team, which includes the following:</th>
</tr>
</thead>
<tbody>
<tr>
<td>• contributing to the multidisciplinary discussion and patient assessment/care planning decision of the team at their regular meetings;</td>
<td></td>
</tr>
<tr>
<td>• providing expert nursing advice and support to other health professionals in the nurse's specialist area of practice;</td>
<td></td>
</tr>
<tr>
<td>• involvement in clinical audit;</td>
<td></td>
</tr>
<tr>
<td>• leading on patient and carer communication issues and co-ordination of the patient pathway for patients referred to the team - acting as the key worker or responsible for nominating the key worker for the patient's dealings with the team.</td>
<td></td>
</tr>
<tr>
<td>• ensuring that results of patients' holistic needs assessment are taken into account in the decision making;</td>
<td></td>
</tr>
<tr>
<td>• contributing to the management of the service (see note below);</td>
<td></td>
</tr>
<tr>
<td>• utilising research in the nurse's specialist area of practice.</td>
<td></td>
</tr>
</tbody>
</table>

**Notes:**

- "Management" in this context does not mean clerical tasks involving the documentation on individual patients i.e. this responsibility does not overlap with the responsibility of the MDT co-ordinator.
- A list of responsibilities containing all the elements in this measure and the previous measure would encompass all of the four domains of specialist practice required for the role of cancer nurse specialist.
- Additional responsibilities may be agreed.

| **Compliance:** | The list of responsibilities agreed by the lead clinician of the MDT and the core nurse specialist(s). |
### Attendance at National Advanced Communication Skills Training Programme

**11-2F-221** At least those core members of the team who have direct clinical contact with patients should have attended the national advanced communications skills training.

**Notes:**
- This measure applies only to those disciplines which have direct clinical contact and which are named in the list in the MDT structure measure for core membership.
- Also, it applies only with regard to members which are in place i.e. if a team lacks a given core member from that list, it should still be counted as compliant with this measure provided those members which are in place, comply.
- The relevant disciplines include medical, surgical, nursing and allied health professionals.
- The reviewers should record which core members of those relevant, are non-compliant.

**Compliance:** Written confirmation of the MDT members who have attended the national advanced communication skills training programme.

### Extended Membership of MDT

**11-2F-222** The MDT should provide the names of members of the extended team for named roles in the team.

If they are not already offered as core team members, the named extended team for the MDT should include:
- cytopathologist;
- core member of the specialist palliative care team;
- anaesthetist/intensivist.

**Notes:**
- The anaesthetist/intensivist should at least represent this specialty at MDT operational policy meetings and co-ordinate this aspect of the MDT's activities.
- The MDT may choose to name additional extended team members.
- Although there is not a requirement to have a named social worker as part of the extended team, there should be arrangements in place to access a social worker when required.

**Compliance:** Name of each extended team member with their role agreed by the lead clinician of the MDT.

### PROVIDING PATIENT CENTRED CARE

### Patient Permanent Consultation Record

**11-2F-223** The MDT should be giving patients the opportunity of a permanent record or summary of at least a consultation between the patient and the doctor when the following are discussed:
- diagnosis;
- treatment options and plan;
- relevant follow up (discharge) arrangements.

**Note:**
- The MDT may, in addition, offer a permanent record of consultations undertaken at other stages of the patient's journey.
- The record of consultation should identify areas discussed during consultation and include a diagram where appropriate which supports the consultation discussion.
- The consultation record provides a permanent summary of the discussion between the doctor and the patient and should always be offered to the patient unless specifically
**Patient Experience Exercise**

The MDT should have undertaken (or be undertaking) an exercise during the previous two years prior to review or completed self-assessment to obtain feedback on patients' experience of the services offered.

The exercise should at least ascertain whether patients were offered:

- a key worker;
- assessment of their physical, emotional, practical, psychological and spiritual needs (holistic needs assessment);
- the MDTs information for patients and carers (written or otherwise);
- the opportunity of a permanent record or summary of a consultation at which their treatment options were discussed.

**Notes:**

- The exercise may consist of a survey, questionnaire, focus group or other method.
- There may be additional items in the exercise. It is recommended that other aspects of patient experience are covered.

The exercise should have been presented and discussed at an MDT meeting and the team should have implemented at least one action point arising from the exercise.

**Compliance:**

- The results of the exercise.
- A report for the action taken.

---

**Provision of Written Patient Information**

The MDT should provide written material for patients and carers which includes:

- information specific to that MDT about local provision of the services offering the treatment for that cancer site;
- information about patient involvement groups and patient self-help groups;
- information about the services offering psychological, social and spiritual/cultural support, if available;
- information specific to the MDT's cancer site or group of cancers about the disease and its treatment options (including names and functions/roles of the team treating them);
- information about services available to support the effects of living with cancer and dealing with its emotional effects.

It is recommended that the information and its delivery to patients and carers follow the principles of the NHS Information Prescription project. ([www.informationprescription.info](http://www.informationprescription.info)).

**Notes:**

- The information prescription should be tailored to the patients/carers needs based on an information needs assessment. Information may be generated and dispensed outside of the clinic environments within an information centre where a clear operational policy between the clinic and information centre is in place which identifies how clinic records are updated and that facilities and resources within the information centre are appropriate to providing such a service.
The information prescription should be composed of information from the national pathways supplemented with national and local accredited information.  

### Compliance

The written (visual and audio if used - see note below) material.  

**Notes:**

It is recommended that it is available in languages and formats understandable by patients including local ethnic minorities and people with disabilities. This may necessitate the provision of visual and audio material. For the purpose of self-assessment the team should confirm the written information which is routinely offered to patients.

<table>
<thead>
<tr>
<th>Individual Patient Treatment Plans</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>11-2F-226</strong></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td><strong>Note:</strong></td>
</tr>
<tr>
<td><strong>Compliance:</strong></td>
</tr>
<tr>
<td><strong>Notes:</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>CLINICAL GUIDELINES</th>
</tr>
</thead>
<tbody>
<tr>
<td>The responsibility for review purposes for clinical guidelines lies with the lead clinician of the MDT and Chair of the NSSG. For compliance, the NSSG in consultation with the MDTs, should produce the agreed network-wide clinical guidelines. The individual MDT for their compliance with this measure should agree to them.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>MDT Agreement to Network Guidelines for the Management of Upper GI Cancer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>11-2F-227</strong></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
</tbody>
</table>
**MEASURE DETAILS & DEMONSTRATION OF COMPLIANCE**

**Notes:**
- A diagnostic-only team would usually refer all patients directly to a specialist team.

**Compliance:**
The clinical guidelines agreed by the lead clinician of the specialist team and the Chair of the NSSG.

**Note:**
It is recommended that this essential information is recorded on an MDT proforma as well as in individual patients notes.

---

**REFERRAL GUIDELINES**

The format of these measures is specific to UGI cancer. In view of (a) the various possible configurations of the service and (b) the need to have agreed the particular group of configuration for the network, the responsibility for assessment purposes for referral guidelines lies with the lead clinician of the MDT and the Chair of the NSSG. For compliance the NSSG should produce agreed guidelines and the individual MDT, for their compliance should agree them.

**MDT Agreement to Network Referral Guidelines Between Teams/Diagnosis & Assessment**

**11-2F-228**
The MDT should agree referral guidelines which includes the following:
- to what extent and in what circumstances the referring diagnostic teams may further investigate a patient after the diagnosis of malignancy and before referral to the specialist team;
- that patients who need specialist care are referred to (name of team being reviewed) from the (name of referring diagnostic and diagnostic/local care teams);
- that patients who need local care are referred to (name of team being reviewed) from the (name of diagnostic teams referring for local care), (applies to specialist teams also providing local care);
- that patients who need specialist care in another network, are referred to (name of team in the other network) from the (name of the team being reviewed).

**Notes:**
- Specialist care and local care are defined in the introduction to the UGI measures.
- It is strongly recommended that when patients are referred for care to another team all members of the referring MDT refer patients with a given cancer type to the same named team.

**Compliance:**
The referral guidelines agreed by the lead clinician of the MDT and Chair of the NSSG.

**Note:**
Specialist teams may receive referrals from diagnostic and diagnostic/local care teams in other networks on grounds of minimum catchment populations. The referral guidelines should then name the relevant teams in the other (referring) networks with their host hospitals.

---

**IMAGING GUIDELINES**

The responsibility for review purposes for imaging guidelines lies with the lead clinician of the MDT and Chair of the NSSG. For compliance, the NSSG in consultation with the MDTs, should produce the agreed network-wide imaging guidelines. The individual MDT for their compliance with this measure should agree to them.

**MDT Agreement to Network Imaging Guidelines Diagnosis/Assessment**

**11-2F-229**
The MDT should agree imaging guidelines for diagnosis and review. The guidelines should address:
- imaging modalities;
- their specific indications.

**Compliance:**
The imaging guidelines agreed by the lead clinician of the MDT and the Chair of the NSSG.
The responsibility for review purposes for pathology guidelines lies with the lead clinician of the MDT and Chair of the NSSG. For compliance, the NSSG in consultation with the MDTs, should produce the agreed network-wide pathology guidelines. The individual MDT, for their compliance with this measure should agree to them.

<table>
<thead>
<tr>
<th>MDT Agreement to Network Pathology Guidelines Diagnosis/Assessment</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>11-2F-230</strong></td>
</tr>
<tr>
<td>The MDT should agree pathology guidelines for the diagnosis and assessment. The guidelines should address:</td>
</tr>
<tr>
<td>• laboratory and histopathology/histochemical investigations;</td>
</tr>
<tr>
<td>• their specific indications.</td>
</tr>
<tr>
<td><strong>Compliance:</strong> The pathology guidelines agreed by the lead clinician of the MDT and the Chair of the NSSG.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Agreed Collection of Minimum Dataset</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>11-2F-231</strong></td>
</tr>
<tr>
<td>The MDT should be recording its agreed part of the MDS, according to the network data collection specification, in an electronically retrievable form.</td>
</tr>
<tr>
<td><strong>Compliance:</strong> Anonymised examples of the recorded data for individual patients.</td>
</tr>
<tr>
<td><strong>Note:</strong> For the purpose of self assessment, the team should confirm that they started to record the MDS.</td>
</tr>
</tbody>
</table>
### Network Audit

#### Introductory Notes
For review purposes a network audit project is an audit project related to the cancer site or sites of the NSSG and the activities of its MDTs. The same project should be carried out by all MDTs for that cancer site in the network, each team’s results being separately identified. The individual MDTs, for compliance with their relevant MDT measure, should agree to participate in the audit. See appendix 1 for audit.

#### Network Audit

| 11-2F-232 | The MDT should agree to participate in the network audit project agreed by the NSSG. The MDT should annually review the progress of the project or present the results of the completed network audit project to the NSSG for discussion at one of their meetings.  

**Notes:**

*For MDTs which have previously been peer reviewed the project should have been completed since that previous peer review.*  

**Compliance:**
The audit agreed by the lead clinician of the MDT and the Chair of the NSSG. Written confirmation of review of progress of audit sufficient to show compliance with the measure.

#### Discussion of Clinical Trials

| 11-2F-233 | The MDT should produce a report at least annually on clinical trials, for discussion with the NSSG. The report should include:

- Details of the MDT’s trials portfolio including the extent of local provision of the national portfolio.
- The MDT’s recruitment to the portfolio, including the extent of delivery against the locally agreed timescales and targets.
- The MDT’s programme for improvement for the above, as proposed to the NSSG.

The MDT should agree a final programme for improvement at the NSSG discussion meeting.

**Note:**

*For compliance with this measure the MDT should produce a proposed programme for improvement and, at the discussion with the NSSG, settle on a mutually agreed programme between the participants of the meeting.*

In addition, applicable only to MDTs dealing with the following cancer sites:

- Leukaemia
- Lymphoma
- Germ cell malignancy
- Bone and/or soft tissue sarcoma
- Brain and CNS malignancy
- Malignant melanoma

The MDT should produce a report on clinical trials, covering the above points, for TYA patients, for discussion at the teenage and young adults’ cancer network co-coordinating group (TYACNCG).

The MDT should agree a final programme for improvement for TYA clinical trials with the TYACNCG.

**Note:**

*The TYACNCG’s current list of trials and studies suitable for TYAs may not include any of those malignancies dealt with by the MDT under review, in which case this is not applicable for the current assessment in question.*
### Joint Treatment Planning for TYAs

**11-2F-234** For each patient in the TYA age group, the MDT should agree the following decisions with the TYA MDT and record them as part of that patient's joint treatment planning decision:

- the multidisciplinary treatment planning decision (i.e. to which modality(s) of treatment-surgery, radiotherapy, chemotherapy, biological therapy or supportive care, or combinations of the same, they are to be referred to for consideration);
- the named consultant in charge of each modality of definitive treatment and the named person in charge of organising arrangements for the age-appropriate support and care environment including those when the treatment is delivered outside the PTC facility.

For those in the age range 19 to the end of their 24th birthday, the MDT should record the choice of treatment location, made by the patient, in particular, whether it is the TYA facility or which of the named designated hospitals for TYAs.

**Notes:**

*Patients in the age range 16 to the end of their 18th birthday should be treated in the PTC.*

*The date of joint agreement to the planning and of the patient’s choice of treatment place may be later than the date of the initial treatment planning discussion by the MDT.*

**Compliance:** The reviewers should ask to see examples of the treatment planning decision record of patients from the TYA age group. Evidence of joint agreement should be by individual TYA patient decision records of the site-specific MDT being authorised by a core member of the TYA MDT.

**Note:**

*If the MDT has had no such patients referred since the last assessment/review this part of the measure is considered to have been complied with. The overall compliance depends then, only on the non-TYA aspects of this measure.*
Appendix 1

Ground Rules for Networking

Introduction

These ground rules preserve the principles underpinning clinical networking. The principles may be summarised as follows:

- They prevent destructive competition between MDTs for their catchment populations.
- They prevent destructive competition between NSSGs for their associated MDTs.
- They allow the development of consistent, intra- and inter-team patient pathways which are clinically rational and in only the patients’ best interests instead of in the vested interests of professional groups or of NHS statutory institutions.

Before a first peer review assessment of any services which, from the networking point of view, come under the governance of a strategic clinical network (SCN), there should be an agreement between the relevant SCNs which describes which provider and commissioner networks come under the governance of each particular SCN. The agreement should delineate the boundaries and list the constituent services and commissioners of those networks. On principle, a single SCN should be agreed as being responsible for the network. This specifies the governance framework within which the networks are placed. Ideally this would apply to all services in a geographical area. However, the arrangements in terms of the governance and ownership of staff and facilities may not be coterminous across different disease sites spread over a similar geographical area. The network function will therefore be reviewed at a disease site specific level. The term ‘network’ in these measures refers to the disease site clinical network unless otherwise specified. The geographical extent of this and the physical facilities and hospital sites involved should be agreed between the relevant SCNs prior to review, and a named SCN should be considered having ownership and requiring/commissioning the review. This principle becomes especially important for cases of clinical networks for the rarer cancers where catchment areas may overlap those of more than one SCN.

NSSGs

- The NSSG should be the only such NSSG for the MDTs which are associated with it.
- For cancer sites where there is only one level of MDT, the NSSG should be associated with more than one MDT.
- The NSSG should be associated with more than one MDT. For cancer sites where there is a division into more than one level of MDT, i.e. into local and specialist/supranetwork MDTs, the NSSG need only be associated with one specialist/supranetwork MDT as long as it is associated with more than one MDT for the cancer site overall.

Notes: The NSSG need only be associated with one specialist/supranetwork type MDT but may be associated with more than one.

Cross Cutting Groups

These currently include network groups for:

- Chemotherapy
- Radiotherapy
- Acute Oncology

These groups need to have working relationships with the hospitals/services system and also the NSSGs / MDTs system, if they are to fulfil their role of acting as leaders of the networking process. Because these groups are service specific, not cancer site specific, it seems most important to lay down ground rules to ensure clarity and co-ordination across a given cross cutting service within a network, and leave ground rules regarding the relationship with NSSGs/MDTs, at a more informal and flexible level. The term ‘network’ here refers to the networking arrangements and coverage of the service in question.
These services are required to have local multiprofessional management teams. These are not equivalent to the site specific groups and are treated differently in the measures. The ground rules for MDTs do not apply to them.

- The network group for a given service should be the only such group for that service for all the hospitals/services it is associated with.
- The equivalent reciprocal ground rules to this for hospitals and services would be; any given hospital should be associated with only one network group for any given service, and any service should be associated with only one network service group.
  
  Note: Hospitals and services are mentioned separately because, for the purposes of peer review and data gathering, it has been necessary to clearly define individual services and delineate their boundaries in terms of staff and facilities. Sometimes a declared 'service' may cross more than one hospital.

MDTs

For MDTs dealing with cancer sites for which the IOG and measures recommend only one level of MDT (i.e. no division into local and specialist or their equivalent. e.g. Breast MDTs):

- The MDT should be the only such MDT for its cancer site, for its catchment area.
  
  Notes: The principle of a given primary care practice agreeing that patients will be referred to a given MDT is not intended to restrict patient or GP choice. A rational network of MDTs, rather than a state of destructive competition can only be developed if i) there is an agreement on which MDT the patients will normally be referred to and ii) the resulting referral catchment populations and/or workload are counted, for planning purposes. It is accepted that individual patients will, on occasion, be referred to different teams, depending on specific circumstances.

- This ground rule does not apply to the carcinoma of unknown primary (CUP) MDT or the specialist palliative care (SPC) MDT. This is because, for this ground rule to be implementable, it is necessary to define a relevant disease entity in terms of objective diagnostic criteria which governs referral at primary care level. This is not possible for CUP or SPC, by the nature of these practices.

- The MDT should be the only such MDT for its cancer site on or covering a given hospital site.

  Note: This is because for patient safety and service efficiency, there should be no rival individuals or units working to potentially different protocols on the same site. This does not prevent a given MDT working across more than one hospital site. Neither does it prevent trusts which have more than one hospital site, having more than one MDT of the same kind, in the trust. This ground rule does not apply to SPC MDTs, since there may be more than one distinctive setting for the practice of SPC on a single given hospital site.

- The MDT should be associated with a single named network site specific group (NSSG) for the purposes of coordination of clinical guidelines and pathways, comparative audits and coordination of clinical trials.
  
  Note: MDTs which are IOG compliant but deal with a group of related cancer sites, rather than a single site, may be associated with more than one NSSG, but should have only one per cancer site. e.g. A brain and CNS tumours MDT also dealing with one or more of the specialist sites such as skull base, spine and pituitary could be associated with a separate NSSG for each of its specialty sites.
For cancer sites for which there is a division into local, specialist and in some cases, supranetwork MDTs, the following apply to the specialist/supranetwork MDTs. The above ground rules still apply to the 'local' type MDTs.

- The specialist/supranetwork MDT should be the only such specialist/supranetwork MDT for its cancer site, for its specialist/supranetwork referral catchment area.
- The specialist/supranetwork MDT should be the only such specialist/supranetwork MDT for its cancer site on or covering a given hospital site.
- The specialist MDT should act as the 'local' type MDT for its own secondary catchment population. If a supranetwork MDT deals with potentially the whole patient pathway for its cancer site, this ground rule applies to the supranetwork MDT. If it deals with just a particular procedure or set of procedures, not potentially the whole patient pathway, it does not apply.

*Note: This is in order that the specialist/supranetwork MDT is exposed to the full range of clinical practice for its cancer site. The specialist MDT should be associated with a single named network site specific group (NSSG), (or possibly one per individual cancer site, as above) for the purposes of coordination of clinical guidelines and pathways, comparative audits and coordination of clinical trials.*
Appendix 2

Roles and Responsibilities

Introduction

Role of the NSSG

The NSSG should be multidisciplinary; with representation from professionals across the care pathway; involve users in their planning and review; and have the active engagement of all MDT leads from the relevant associated organisations.

The NSSG should:

- agree a set of clinical guidelines and patient pathways to support the delivery of high quality equitable services across the network;
- review the quality and completeness of data, recommending corrective action where necessary;
- produce audit data and participate in open review;
- ensure services are evaluated by patients and carers;
- monitor progress on meeting national cancer measures and ensure actions following peer review are implemented;
- review and discuss identified risks/untoward incidents to ensure learning is spread;
- agree a common approach to research and development, working with the network research team, participating in nationally recognised studies whenever possible.

Responsibilities of the MDT lead clinician

The MDT lead clinician should:

- ensure that designated specialists work effectively together in teams such that decisions regarding all aspects of diagnosis, treatment and care of individual patients and decisions regarding the team's operational policies are multidisciplinary decisions;
- ensure that care is given according to recognised guidelines (including guidelines for onward referrals) with appropriate information being collected to inform clinical decision making and to support clinical governance/audit;
- ensure mechanisms are in place to support entry of eligible patients into clinical trials, subject to patients giving fully informed consent;
- overall responsibility for ensuring that the MDT meetings and team meet peer review quality measures;
- ensure attendance levels of core members are maintained, in line with quality measures;
- provide the link to the NSSG either by attendance at meetings or by nominating another MDT member to attend;
- ensure MDT's activities are audited and results documented;
- ensure that the outcomes of the meeting are clearly recorded, clinically validated and that appropriate data collection is supported.
<table>
<thead>
<tr>
<th>Measure number</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>1A-201f</td>
<td>Revised and Included in NSSG measures 1C-113f to 1C-116f</td>
</tr>
<tr>
<td>1A-202f</td>
<td>Revised and Included in NSSG measures 1C-113f to 1C-116f</td>
</tr>
<tr>
<td>1A-203f</td>
<td>Revised and Included in NSSG measures 1C-113f to 1C-116f</td>
</tr>
<tr>
<td>1A-204f</td>
<td>Revised and Included in NSSG measures 1C-113f to 1C-116f</td>
</tr>
<tr>
<td>1A-205f</td>
<td>Revised and Included in NSSG measures 1C-113f to 1C-116f</td>
</tr>
<tr>
<td>1C-103f</td>
<td>Revised</td>
</tr>
<tr>
<td>1C-104f</td>
<td>Revised</td>
</tr>
<tr>
<td>1C-105f</td>
<td>Revised</td>
</tr>
<tr>
<td>1C-106f</td>
<td>Revised</td>
</tr>
<tr>
<td>1C-113f</td>
<td>Revised</td>
</tr>
<tr>
<td>1C-114f</td>
<td>Revised</td>
</tr>
<tr>
<td>2F-125</td>
<td>Revised</td>
</tr>
<tr>
<td>2F-126</td>
<td>Revised</td>
</tr>
<tr>
<td>2F-129</td>
<td>Revised</td>
</tr>
<tr>
<td>2F-228</td>
<td>Revised</td>
</tr>
<tr>
<td>2F-231</td>
<td>Revised</td>
</tr>
<tr>
<td>2F-3</td>
<td>To be replaced with new HPB measures</td>
</tr>
<tr>
<td>2F-4</td>
<td>To be replaced with new HPB measures</td>
</tr>
<tr>
<td>Appendix 1</td>
<td>New</td>
</tr>
<tr>
<td>Appendix 2</td>
<td>Revised</td>
</tr>
</tbody>
</table>